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1 -0-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHORYLCHOLINE

(PLATELET ACTIVATING FACTOR):
INTERACTIONS WITH SHEEP PLATELETS
by
Duane 0. Beaumont

Platelet Activating Factor (PAF) seems to link platelet
function with allergy and inflammation.

Early events

associated with the action of PAF on platelets are poorly
understood, but PAF appears to interact with a platelet
membrane receptor.

Two photoaffinity-labelling analogs of

PAF, diazoacetyl PAF and trifluorodiazoacety1 PAF, were
designed for examining the interaction between PAF and its
platelet receptor.

These photoactive compounds were

selected on the basis of the structure-activity relationship
of PAF, and the general guidelines of the photoaffinity
labelling technique.
synthesis

Some progress has been made in their

and characterization.

The standard platelet aggregation assay was
unreliable in testing the activity of PAF analogs on sheep
platelets.

The response of sheep platelets to PAF was

characterized in terms of aggregation, serotonin release, ATP
release and phosphatidic acid formation but also with a new
and more satisfactory method based on platelet shape change.

The development of the latter was based on microscopic and
rheooptic observations but is also supported by theoretical
considerations.

A shape change parameter (SCP) was defined

and, therefore, the method is called the SCP assay.

The SCP

assay demonstrated, for the first time, that platelet shape
change is a response sensitive to small changes in nanomolar
PAF concentrations (less than an order of magnitude).
The SCP assay proved superior to the aggregation assay
for the characterization of the photoaffinity-labelling
analogs in a comparison of sensitivity to PAF, PAF analogs
and modulators of platelet activation.

A wider range of PAF

concentrations could be distinguished with the SCP assay,
and it was more sensitive to structural differences between
lyso-PAF, PAF, propanoyl PAF, butanoyl PAF, hexanoyl PAF and
oleoyl PAF than the aggregation assay.

The order of

relative activities observed with analogs did not differ
between the assays.

The SCP assay extended the range of

detectable PAF levels to concentrations lower than those
measurable by aggregation, serotonin release or ATP release.
Modulators of platelet activation such as prostacyclin,
TTVIB-S and i ndomethac i n, had similar effects on the magnitude
of response by aggregation and SCP assay.

Both ATP release

and SCP were inhibited in proportion to the concentration of
prostacyclin.

Neither aggregation nor SCP was affected by

indomethacin at concentrations that inhibit the response to
thrombin and collagen, supporting the definition of PAF as
2

mediator of a "third pathway" of platelet activation.
The relationships of shape change and platelet
aggregation to platelet activation suggest that the new assay
will be of more value than the aggregation assay in
characterizing the initial interaction of PAF with platelets.
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1.
1.1.

Int r oduc tion

Platelet Fiin^tinn

Platelet function is implicated in artherogenesis and
contributes to the clinical problems of thrombosis and
embolism, heart attack, stroke, and metastasis.

Platelets

support these pathological processes by complex mechanisms
which begin with platelet aggregation and blood coagulation.
Through the coordinated processes of platelet aggregation
and blood coagulation, platelets help maintain vascular
integrity.

This primary hemostatic role requires both a

sensitivity to stimuli such as collagen and thrombin, and an
ability to elaborate other mediators of aggregation and
b1ood coagu1 ation .
Platelets are the most numerous formed elements in blood
and are found in humans at normal concentrations ranging from
200 , 000 to 450,000/mI.

They are actually fragments of

megakaryocytes, 1-3 pm in diameter, which survive only ten
days after release from the bone marrow.

Although platelets

lack nuclei, they possess mitochondria, an elaborate
microtubular system, and other organelles including two
special types of cytoplasmic granules.

These cytoplasmic

granules secrete their contents into the plasma when the
platelet is stimulated.

The dense granules contain Ca 2 + ,

adenosine 5’-diphosphate (ADP), adenosine 5’-triphosphate
(ATP), and serotonin.

The alpha granules, less electron
1
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dense than the others, store at least two proteins that are
unique to platelets — platelet derived growth factor (FDGF)
and platelet factor 4 (PF4).

The alpha granules also

contain fibrinogen and Factor V which are important
components in the cascade of reactions leading to blood
coagu1 ation.
Platelet mechanisms which act to restore the integrity
of blood vessels operate through platelet plug formation,
blood coagulation, and clot retraction,

The sequence of

events which occurs upon tissue injury is adhesion of
platelets to exposed collagen, followed by the
platelet-release reaction and aggregation, blood
coagulation, and clot retraction.

Platelets form the

primary hemostatic plug in response to both collagen and ADP,
the latter being released from platelets and extravascu1ar
tissue.

Thrombin accumulates on the platelets and

stimulates them to a secondary phase of aggregation which,
unlike the primary phase, is irreversible,

The initial

appearance of thrombin follows activation of the extrinsic
pathway of blood coagulation by tissue factor from injured
tissue, but its continued generation is related to platelet
function.

Platelets support blood coagulation through the

release of clotting factors and platelet factor 3, and by
promoting specific steps of the intrinsic pathway,

Platelet

factor 3 is a poorly defined collection of phospholipids
from the platelet which contributes to the formation of

3

micelles for the surface-dependent clotting reactions.
Among the other ways in which platelets help to promote
blood coagulation are processes whereby ADP-stimu1 ated and
col 1agen-stimu1ated platelets activate clotting factors, as
well as an enhancement of reactions leading to Factor Xa
formation.

Finally, platelets supply throbosthenin , a

contractile protein for clot retraction which does not occur
in the absence of platelets.
Although platelet release is important to platelet
function in hemostasis, it also contributes to
non-hemostatic processes.

Among the constituents of the

cytoplasmic granules are some substances such as serotonin,
PDGF, and PF4 which do not assist platelets in hemostasis.
No function of PDGF has been associated with hemostasis.
The vasoconstricting effect of serotonin is not necessary to
hemostasis since its lack in platelets does not result in
abnormality.

Since it is doubtful that all the substances of

cytoplasmic granules have been identified, the possibility of
other non-hemostatic mediators remains.

Upon stimulation of

platelets, non-preformed substances are produced that have
diverse functions: arachidonic acid (AA) , cyclic
endoperoxides , 1eukotrienes , thromboxane A£ (TXAg) and
pros taglandins.

Cyclic endoperoxides and AA can trigger

platelet aggregation, and TXAg can cause serotonin release.
Various prostaglandins such as PGI2’

and P(^E2 also

modulate platelet activation, but their increasingly
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recognized significance in other areas of physiology hints at
wider roles for platelets.

Further, the fact that platelets

are stimulated by diverse molecular types suggests that
platelet function may interface with many processes.
Among the many activators of platelets are ADP
epinephrine, norepinephrine, serotonin, vasopressin,
thrombin, trypsin, snake venom, collagen, fatty acids,
glycoproteins, endotoxin, viruses and antigen-antibody
comlexes (Ag-Ab).

This growing list must now include a novel

agent of platelet activation which provides a strong link
between platelet, immune, and inflammatory processes.

This

molecule, also recognized as the most potent of platelet
aggregating agents, is called Platelet Activating Factor
(PAF), PAF-acether, or AGEPC.
1.2.

History nf PAF

The history of PAF can be traced back to 1966 when
Barbaro and Zvaifler (1966) observed a leukocyte-dependent
release of histamine from rabbit platelets.

Later,

Siraganian and Osier (1971) detected a soluble principle
that served as an inhibitor in this interaction of
leukocytes and platelets.

This intermediate was named

Platelet Activating Factor by Benveniste (Benveniste et al.,
1972) who then embarked upon its characterization.
Benveniste’s group discovered that its release from
basophils was IgE-dependent, and in 1 974 , reported that it
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was found in human leukocytes (Benveniste, 1974).

That

human platelets exhibit a sensitive response to PAF, and the
characteristics of that response in aggregation and release,
were documented by Benveniste’s group in 1975 (Benveniste et
al . , 1 975 ).

By 1 977 , there was evidence that the compound

was a phospholipid possessing a choline moiety, but it was
not until 1979 that its structure was fully elucidated
(Demopoulos et al., 1979).

PAF is an ether-phospholipid

— 1 -0-alky1 -2-acety1-sn-glycero-3-phosphoryIcholine — with
a saturated alkyl chain of 16 to 18 carbons,

The total

synthesis of the active compound, achieved in 1980 (Godfroid
et al., 1980), was followed by a succession of studies of
the activity of various synthetic analogs of PAF (Wykle et
al., 1981; Satouchi et al . , 1981a; Wykle et al., 1 982 ;
Satouchi et al., 1981b).

From these experiments came

precise information about the relationship between the
structural features of PAF and its potency in platelet
aggregation.

With human platelets, native PAF produced

measurable responses at concentrations less than one
nanomolar.
1 .3 .

PAF in Physiology

The fact that PAF was produced by IgE-sensitized
basophils provided the first hint that PAF could be involved
in immediate-hypersensitivity reactions, and demonstrated a
connection between immune processes and platelets.

Evidence

in support of this relationship came from studies that

6

demonstrated the production of PAF by cells other than
basophils, and its effects on a variety of tissues.
PAF is released from most cells that participate in
inflammatory processes, and while these cells perform the
related functions.

The cellular sources of PAF include

basophils, macrophages, blood monocytes, neutrophils and
eosinophi1s .

The presence of PAF in basophils was

demonstrated when rabbit leukocytes released PAF in response
to anti-IgE antiserum (Benveniste et al., 1972; Betz et al.,
1 980 ) .

This release is specific; anti-IgG antiserum does

not stimulate the release of PAF from basophils (Benveniste
et al., 1972).

There is some evidence that human basophils

also release PAF (Clark et al
but this

is controversial

1976; Camussi et al., 1981a),

in view of contradictory results

(Benveniste and Vargaftig, 1983).

Mouse peritoneal

macrophages liberate PAF during zymosan-phagocytos i s , but
this PAF-releasing ability is improved upon pretreatment
with immunogenic material

(Roubin and Benveniste, 1981).

Alveolar macrophages of asthmatic patients release PAF in
greater quantities than those from healthy donors (Arnoux et
al.,

1981) .

PAF has also been formed upon stimulation of

sensitized alveolar macrophages with specific allergen
(Benveniste et al., 1979; Arnoux et al., 1981).

The release

of PAF from neutrophils, both human and rabbit, occurs when
they are stimulated by phagocytosable particles (Lynch et
al., 1 979 ; Lotner et al . , 1 980 ).

Platelets themselves

7

release PAF, as seen with rabbit platelets stimulated by
collagen, thrombin or Ca 2 + ionophore A23187 (Chignard et
al. , 1 979; 1 980 ), and with human platelets stimulated with
the latter (Chignard et al, 1979).

The release of PAF is

dependent on the presence of extracellular Ca 2 + and albumin.
The activity of PAF is not restricted to platelets,
which respond by aggregating and releasing, but extends to
PAF

blood cells which do not have a primary hemostatic role,

stimulates the aggregation of monocytes (Yasaka et al ., 1 982 )
and neutrophils (Camussi et al. , 1981b; Henson, 1981).

Since

the intravenous administration of PAF to rats and baboons
also causes basopenia (McManus et al., 1980; 1981),
basophils, too, can be aggregated by PAF.

PAF exerts

chemotactic and release stimulating effects on human
neutrophils (Benveniste and Vargaftig, 1983), and stimulates
the formation of superoxide anion in the same (Shaw et al.,
1981).
PAF is classified as a mediator of inflammation, based
upon observable effects which suggest a possible role in
immediate-hypersensitivity reactions such as anaphylaxis and
immune complex deposition.

The term "mediator” has been

adopted to refer to various biological substances which can
modulate inflammatory processes (Pinckard, 1983).

The

substances under this classification usually have a wide
range of pharmacological actions relevant to inflammation,
and include histamine, serotonin, arachidonic acid

8

metabolites, and the complement-derived anaphy1atoxins .

PAF

displays vasoactive properties in common with histamine,
serotonin, bradykinin, and prostaglandin D2 (PGD2)

causing

vasoconstriction and enhancing vascular permeability.

In

addition, like histamine and some arachidonic acid
metabolites such as slow reacting substance of anaphylaxis
(SRS-A) and
muscle.

PAF stimulates the contraction of smooth

PAF also causes bronchoconstriction , and with a

potency greater than any other mediator.

The chemotactic

properties of mediators such as histamine and some
arachidonic acid metabolites (from both the 1ipooxygenase
and the cyclooxygenase pathways) influence inflammation by
directing the migration of inflammatory cells.

PAF,

likewise, can cause the directed migration of inflammatory
cells.
Mediators often act indirectly by interaction with
other mediat or-bearing cells but some of the effects of PAF
are direct.

Since PAF activates platelets and neutrophils,

some of its effects could be due to the release of
histamine, serotonin, TXA2, and other arachidonic acid
metabolites from these cells.

An example of a

platelet-dependent effect of PAF is bronchoconstiction , which
does not occur in platelet-depleted systems, and has been
invoked as an explanation of bronchospasms in human pathology
(Benveniste and Vargaftig, 1983).

In contrast,

cardiovascular effects of PAF, resulting in systemic

9

hypotension, occur in platelet-depleted animals and are,
therefore, pi at elet-independent.

The dependence of PAF

action on other mediators also relates to its vasoactive and
smooth muscle-contracting properties.

The vasoactivity of

PAF is maintained in the presence of the histamine
antagonist, chlorpheniramine, which blocks increases in
vascular permeability due to histamine.

This activity is not

affected by neutropenia; PAF acts directly on endothelial
cells in postcapillary venules.

PAF causes guinea pig smooth

muscle to contract at a slower rate of onset than histamine
and more rapidly than SRS-A, but this is unaffected by
antagonists of either mediator.

This action of PAF is

therefore independent of SRS-A and histamine.
Direct evidence that PAF is a mediator in anaphylactic
reactions comes from the results of a systematic approach to
the study of effectors in immediate hypersensitivity.

The

role of PAF was established with an "IgE-rabbit" model which
allowed routine examination of the intravascular and
physiological reactions due to IgE-mediated degranulation of
basophils and mast cells responding to intravenous antigen
(Ag) challenge (Pinckard, 1983).

In the first step, the

characteristic response of IgE-rabbits was determined to be
systemic anaphylactic shock, leading to death within minutes,
and accompanied by thrombocytopenia and neutropenia.

PAF was

released into the plasma 30 - 60 seconds after the antigenic
challenge and was physiochemically and functionally identical
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to PAF released from IgE-sensitized basophils in vitro,

The

features of the response, including PAF release, could be
induced in normal nonimmunized rabbits by stimulation after
passive transfusion of IgE-sensitized basophils.

Further, a

desensitization of platelets to PAF in vitro also occurred
during IgE anaphylaxis.

Thus, PAF was released, and mediated

an interaction between basophils and platelets during
IgE-induced systemic anaphylaxis.

In the second step, the

effects of infusing synthetic PAF at concentrations released
during anaphylaxis were shock, thrombocytopenia, neutropenia
and death within 2 minutes, consequent to systemic
hypotension and respiratory arrest.

The cardiovascular and

pulmonary responses to synthetic PAF were the same as those
that occurred in IgE-induced systemic anaphylaxis.

Other

studies suggest that the acute pulmonary hypertension with
resultant right ventricular strain and reduced cardiac
output which are characteristic of the first stage of
systemic anaphylaxis, as well as the systemic hypotension of
the second stage, are modulated by PAF independently of
platelets.

The respiratory failure of anaphylaxis is

related to both PAF-induced pulmonary hypertension and a
sequestration and activation of platelets and neutrophils in
the lung.

Changes in peripheral vascular resistance and

vascular leakage contribute to the systemic hypotension and
reflect the combined action of PAF and other mediators,
particularly histamine (Pinckard, 1983).
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The vasoactive potential of PAF has been compared to
that of histamine in human studies which suggest a possible
role in another type of anaphylaxis,

Intradermal injections

of PAF result in immediate skin blanching suggestive of acute
vasoconstriction, and frequently lead to burning and
pru r i t i s .

An intense wheal and flare reaction occurs with

characteristics typical of a reponse to histamine, but PAF is
estimated to be 1000 times more potent than histamine
(Pinckard , 1 983 ).

Thus, PAF may prove important in allergic

reactions of cutaneous anaphylaxis, especially if mast cells
are capable of releasing this mediator.
A role for PAF in immune complex deposition is suggested
Further ,

by the sensitivity of platelets to Ag-Ab complexes.

immune complex deposition in rabbits involves PAF-mediated
histamine release (Benveniste and Vargaftig, 1983; Henson and
Cochrane, 1971; Benveniste et al. , 1 976).

One of several

immune complex syndromes, the Arthus reaction,

is influenced

by the release of PAF (Kravis and Henson, 1977).
removal of deleterious materials such as bacterial

The
immune

complexes from the blood stream is believed to be a normal
physiological function which PAF may influence by its
contribution to enhanced vascular permeability (Benveniste
and Vargaftig, 1983).

Actual proof of important roles of PAF

in both normal homeostasis and pathophysiological processes
awaits the development of specific antagonists of PAF.
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1.4.

Platelet Activation and PAF

Platelets are the functional units through which the
actions of PAF in hemostasis, immediate hypersensitivity, and
bronchospasm may be related most directly.

Hence, the

central point of most research with PAF continues to be its
aggregatory and release effects on platelets, in comparison
with other platelet stimulants.

Implicit in such research

is the idea that a study of platelet aggregation and release
will yield significant information about the early events in
platelet activation and associated mechanisms.

It is widely

believed that the final common pathway of platelet
activation by a variety of agents is the movement of Ca 2 +
from intracellular reservoirs into the cytoplasm.
clues to earlier events

Scattered

in activation allow only the

preliminary designation of pathways and the tentative
identification of intermediates.
The results of aggregation studies done in the presence
of aspirin, indomethacin, or scavengers of ADP reveal the
possibility of three broad pathways of platelet activation.
A first pathway is mediated by ADP, a second by metabolites
of arachidonic acid, while a third pathway is indicated by
the observation of platelet aggregation without a requirement
for the mediators of the other two pathways.

The term

mediator is used loosely to indicate the specific molecular
requirement established in the inhibition studies by which
the first two pathways were defined.

Accordingly, ADP and

13
certain metabolites of arachidonic acid are mediators of
platelet activation, but another mediator is suggested by the
characteristics of the response of platelets to thrombin and
collagen.

When platelet aggregation is triggered by

thrombin or collagen, ADP is released from the dense granules
and AA is hydrolyzed from the membrane phospholipids.
Aggregation initiated by small amounts of thrombin or
collagen is blocked, however, when ADP is removed with an
ADP scavenging system such as creatine phosphate with
creatine phosphokinase (CP/CPK), and when the formation of
arachidonic acid metabolites such as cyclic endoperoxides
and thromboxane

is prevented by aspirin or indomethacin.

This inhibition is overcome by higher concentrations of
thrombin or collagen, indicating that these molecules can
activate platelets by a pathway which does not require ADP
or arachidonic acid metabolites.

This pathway is referred

to as the third pathway.
PAF is believed to be a mediator of the third pathway
because it stimulates platelets to aggregate in the presence
of inhibitors of the other two pathways (Cazenave et al .,
1979) and can be released from platelets,

The effect of PAF

is not completely independent of cyclooxygenase; at lower
concentrations of PAF, decreased synthesis of TXA2
accompanies an apparent reduction in the response of
platelets (Miller and Gorman, 1982).

This finding presents

the possibility of a fourth pathway of platelet activation.
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The mechanism of PAF action involves precursor
recruitment from membrane phospholipids to form compounds
like TXA2, phosphatidic acid, and 1 , 2-diacyIglycero1 which
may be intracellular mediators in platelet activation,

The

interaction of PAF with platelets leads to the activation of
phospholipase A2, which hydrolyzes arachidonic acid from the
phospholipids (Shaw et al., 1978).

The supply of

arachidonic acid supports the formation of TXA2, which is an
intracellular trigger of serotonin release.

A rapid

formation of phophatidic acid (PA) is stimulated when
platelets interact with PAF, as with thrombin, ADP, collagen
and Ca 2 + ionophore A231 87 (Siess et al . , 1 983 ; Lapetina and
Siegel, 1983).

Phosphatidic acid is produced, following

stimulation of phosphatidy1inositol-specific phospholipase
C, when the resulting 1 , 2-diacy1glycerol is phosphory1 ated
by diacyIglycerol kinase (Lapetina, 1982). Since
phosphatidic acid is a Ca 2 + ionophore and a fusogen whose
formation characteristically accompanies the stimulation of
platelets, phosphatidic acid may be involved in
intracellular signalling of platelet activation.
1 ,2-DiacyIglycerol is as much a candidate for this role as
phosphatidic acid because it is a substrate in the reaction
by which phosphatidic acid is produced.

Further,

1 ,2-diacyIglycerol is an activator of protein kinase C, a
cAMP-independent enzyme which appears to participate in
transmembrane signalling of platelet activation (Lapetina and
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and Siess, 1983).

The formation of phosphatidic acid

occuring upon PAF stimulation of platelets is paralleled by
the phosphorylation of a 40,000 dalton protein, and this may
result from the activation of protein kinase C by
1,2-diacyIglycerol (Lapetina et al . , 1 983 ).
The characteristics of phosphatidate formation in
platelets support a possible role of PA or 1 , 2-diacyIglycerol
as a universal intracellular mediator of platelet activation.
Phosphatidic acid formation is associated with stimulation by
each of the agents upon which the definition of the three
pathways of platelet activation has been based: ADP,
thrombin, collagen and PAF.

The pattern of sensitivity of

the effects of thrombin and collagen to indomethacin is
identical for PA formation and platelet aggregation.
Further, formation of phosphatidic acid is like aggregation
in that both respond without a requirement for the metabolism
of arachidonic acid.

However, stimulation of

phosphatidy1inositol-specific phospholipase C by arachidonic
acid, and the resulting formation of phosphatidic acid do
require the metabolism of AA via cycloxygenase (Siess et al.,
1 983 ) .

Therefore, at least two pathways are apparent between

the interaction of an agonist with a platelet receptor and
the stimulation of phosphatidy1inositol-specific
phospholipase C leading to phosphatidic acid formation.

If

phosphatidic acid is a universal mediator of platelet
activation, the stimulation of phospholipase C cannot be the
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first consequence of interaction between the activating
agent and
1.5.

its

receptor.

Platelet Reeeptnrs fnr PAF

The idea of specific platelet receptors for PAF
originated from studies utilizing synthetic PAF that
deviated in structure from native PAF (Demopoulos et al. ,
1 979; Hanahan et al. , 1981; Satouchi et al ., 1981b; Tence et
al., 1981; Heymans et al., 1981).

The native compound is a

saturated ether analog of phosphatidylcholine with acetic
acid esterified in the number two position of the glycerol
backbone.

The alkyl group is a mixture of hydrocarbon

chains of 16 or 18 carbons in length,

Modifications of the

polar head group revealed a strict requirement for the
choline moiety since the ethanolamine derivative was some
2000 times less active.

The presence of the ether linkage is

also critical; its replacement with an ester decreases the
activity of the molecule 100 fold,

The strongest suggestion

for the role of a receptor comes from the results of
modifications at position 2:

the enantiomeric form of PAF

(i.e. sn-1) was inactive (Heymans et al . , 1981; Lalau-Keraly
and Benveniste, 1982).

PAF activity also requires a short

acyl chain in the number 2 position of the glycerol backbone.
The results of desensitization studies have provided
more convincing evidence for the existence of a PAF
receptor.

After a first exposure to PAF, washed rabbit

platelets are desensitized such that they do not aggregate
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or release in response to a second challenge but still
aggregate with ADP (Henson, 1976; 1977).

In cross

desensitization studies, PAF from various species caused
desensitization towards each other and also to the
2-propanoyl analog,

However, neither ADP nor the PAF

enantiomer could cause desensitization (Laiau-Keraly and
Benveniste , 1 982 ).
Although the relative activity of PAF analogs
demonstrated specificity of interaction, other criteria of
receptor interaction such as high affinity, saturability and
reversibility have been examined in three binding studies.
In the first binding study, before the availability of
radiolabel1ed ligand, binding was assayed indirectly through
the measurement of serotonin releasing activity of
platelet-suspending medium (Shaw and Henson, 1980).
Saturable binding was observed without an estimate of
nonspecific binding.

The first direct binding study used

radiolabel 1ed PAF on human platelets and demonstrated high
affinity binding with saturability and reversibility (Valone
et al., 1982).

The Scatchard plot was upwardly concave,

indicating possibilities such as two heterogeneous binding
sites and negative cooper ativity between two identical
sites.

Various structural analogs of PAF were tested, and

their relative binding affinities paralleled their relative
platelet aggregating activities.

A third binding study

focused on the interaction of radiolabel1ed PAF with
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isolated plasma membranes from various cell types in rabbits
(Hwang et al . , 1 983 ) .

Again, PAF binding to platelet

membranes occured with high affinity, specificity,
saturability and reversibility.

Thus, all the binding

studies to date provide evidence of a PAF receptor in
platelets, and it appears that this receptor is a part of
the plasma membrane.

While the dissociation constants (eg.

1.36 nM, Hwang et al., 1983; and 36 nM, Valone et al., 1982)
approximate the effective concentration range of PAF in
platelet aggregation and release, the correlations are not
perfect; maximal stimulation in aggregation or release is
achieved at states of submaximal receptor occupancy (Shaw
and Henson, 1 980 ; Valone et al , 1 982 ).
Although the existence of a PAF receptor in platelets
appears to be established, clues to the chemical character of
the receptor are scarce.

Serine-esterase inhibitors block

the activation of platelets by PAF, suggesting the
possibility of a "receptor-enzyme” unit.

However,

serine-esterase inhibitors do not affect the binding of PAF
(Shaw and Henson, 1980).

Other evidence that the receptor

might be protein in character comes from Hwang, whose group
reports a protease sensitivity of PAF binding (Hwang et al . ,
1 983 ) .

The receptor appears also to be heat labile (Hwang

et al. , 1 983 ).
1.6.

Research

Objectives
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This research is concerned with the mechanism by which
PAF stimulates platelets.

Our present understanding of

platelet activation comprises fragmentary pictures of
apparently relevant processes which are hypothetically
connected.

Activation is manifested in aggregation and

release but is related to activation of phospholipase

and

arachidonic acid metabolism, activation of
phosphatidy1inositol-specific phospholipase C, cyclic
nucleotide metabolism, and the mobilization of intracellular
Ca

.

Each of these areas of interest provides various

points of possible focus that are currently under
investigation.

Experimentation in several biological

systems such as rabbit, rat

guinea pig, horse, and human,

supplies results which may highlight common features of
platelet activation.

Studies with sheep, described here,

add to the existing body of information about PAF while
delving into a specific event.

This event is receptor

recognition and binding of PAF which represents the initial
interaction of PAF with platelets.
More complete characterization of PAF receptor binding
is needed to determine responses most closely related to
binding and to identify the receptor itself,

The lack of

full correlation between the relative extent of binding of
PAF and the degree of aggregatory or release response may
relate to desensitization (Shaw and Henson, 1980), but could
also indicate an inadequate assay.

Binding studies may
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provide better correlations than with studies of aggregation
or release if designed around measures of function which
are more closely linked to early events of platelet
activation.

It is hoped that such binding studies will

contribute to locating the PAF receptor and determining its
chemical

identity.

The long term goal of this project is

the isolation, purification and characterization of the
platelet
1.6.1.

receptor
Rpppptor

for PAF.
Isnlfltion

Two general approaches were considered in the design of
this project for the isolation and eventual characterization
of the PAF platelet receptor.

The first scheme requires

exploiting PAF binding as an assay of the PAF receptor in
platelet plasma membranes to evaluate a series of membrane
fractionation steps.

Isolation of the receptor molecule from

the final membrane preparation would be accomplished through
application of macromolecule-purification techniques.
Inherent difficulties in this procedure, such as the loss of
receptor structures through long and tedious membrane
preparation techniques as well as possible uncertainties
associated with the use of the binding assay, make this
approach unattractive.

A second approach, photoaffinity

labelling, is more promising, given the successful
preparation of an appropriate analog of PAF.

In this case,

the radiolabel1ed photosensitive analog of PAF would become
covalently linked to the receptor on intact platelets.

Then
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the PAF-receptor complex could be subjected to membrane
fractionation procedures, followed by electrophoresis, with
the covalently linked and radiolabel1ed ligand serving as a
tracer of

the receptor.

The gains expected from this

approach are the demonstration of

the chemical character of

the receptor molecule, the isolation and purification of

the

intact receptor, and clues to the specific chemical groups
in the PAF binding site.

1 .6.1 .1 .

Phntnaffinity Lfthplling

It was Westheimer, working with chymotrypsin in 1 962 ,
who first applied photochemical probes to the study of
receptors in biological systems (Singh et al . , 1 962 ; Shafer
et al . , 1 966 ) .

Photochemical probes have since then been used

in hundreds of projects.

The first report of the synthesis

and testing of a photoactive phospholipid appeared in 1975
(Chakrabarti and Khorana, 1975), and has been followed by
others dealing mainly with lipid-lipid interactions,

There

are also reports of studies of the interaction of photoactive
phospholipids with proteins but these have developed at a
slower pace (Bisson and Montecucco, 1981).
The photoaffinity labelling technique takes advantage of
the fact that the favorable interactions in 1igand-receptor
binding collectively provide tolerance for some variation in
ligand structure without loss of either selectivity or
strength of binding.

Thus, the biological receptor can
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bind, in place of its normal ligand, an analog carrying a
photolabile group.

Subsequent irradiation of the complex

gives rise to a highly reactive ligand-derived molecule which
covalently labels the receptor site.

Two general criteria

for the selection of an effective reagent (Bayley and
Knowles, 1977) relate to this and are formulated as follows.
Firstly, the precursor should be readily available,
chemically stable (i.e., half life in aqueous solution of
hours or longer), and smoothly photolyzed at wavelengths not
deleterious to the system (or, alternatively, for short
enough periods of time).

Secondly, the photochemically

derived species should be very reactive, of very short half
life, and resistant to rearrangement leading to a less
reactive compound.

If the lifetime of the photochemically

derived species is long and its exchange rate is high, then
the problem of pseudophotoaffinity labelling arises, in
which the technique reduces to simple affinity labelling.
The general strategy adopted in applying the technology
of photoaffinity labelling is to first select a structure
which appears to have the necessary features,

This is the

photoaffinity-1abel1ing analog of the native compound, and
is usually designed so that the photochemically derived
molecule is either a carbene or a nitrene.

The possibilities

are not limited to carbene and nitrene precursors, however,
since the essential aspect of the photoderivatization is the
formation of free radicals upon the homolytic cleavage of
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bonds.

The next step in the stategy is to determine the

biological activity and chemical characteristics of the
photoactive compound (photoaffinity-1abel1ing analog).
Finally, upon satisfaction of the criteria, a radiolabel1ed
version of the photoactive compound is prepared. Thus, one
of the goals of this research project is the selection,
preparation and characterization of photoaffinity-labelling
analogs of PAF according to established guidelines.
1.6.2.

PAF Assay

The characterization of photoaffinity-labelling analogs
of PAF begins with the measurement of biological activity,
and therefore requires a reliable PAF bioassay.

The early

studies to charaterize PAF in biological fluids utilized an
assay designed to distinguish PAF activity from that of
previously known mediators.

Activity was then assessed by

the aggregation of aspirin-treated washed platelets in the
presence of the ADP scavenger CP/CPK.

Since the

purification and ready availability of PAF, its activity has
been measured most precisely by serotonin release, but
platelet aggregation is still

the choice for routine assay.

Serotonin analysis usually involves the assay of the
radiolabel1ed compound long after the addition of stimulant,
while aggregation measurements with the light
transmission-based aggregometer

are immediate.

Platelets are usually studied either in platelet rich
plasma (PRP), prepared by the differential centrifugation of
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blood, or in a washed platelet (WP) preparation generated
from PRP.

The responsiveness of platelets to PAF and other

stimuli can decline appreciably over the time of preparation
and testing.

Because of the lability of platelets,

investigators often specify that their studies were completed
shortly (within an hour) after blood collection.

Significant

changes were seen in both the pattern and magnitude of
aggregation in response to PAF in this research even within
an hour of blood collection.

These observations prompted the

search for measurements of activation that are more reliable
and convenient than either the assay of platelet aggregation
or serotonin release.

Phosphatidic acid formation may be a

more relevant measure of platelet activation than either of
these but it is more difficult to measure (Lapetina et al . ,
1 982 ) .
Lapetina observed that PAF-induced platelet shape change
correlates with phosphatidic acid formation even at low
concentrations of PAF where neither detectable aggregation
nor serotonin release occur (Lapetina et al . , 1 982 ).

This

transformation of platelets from smooth discs to
spheroid-like forms with variously shaped protrusions is the
earliest morphological change in platelets after exposure to
aggregating agents (Born, 1962).

Patscheke reported studies

focusing on the relationship of platelet activation and
platelet aggregation (Patscheke, 1979; Patscheke and Worner,
1977; 1978) which suggested that shape change, and not
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platelet aggregation, represented platelet activation.

In

one study, eleven inducers (not including PAF) of platelet
response were examined.

The initial response to the eleven

agents tested was disc-sphere transformation, an event which
always preceded the onset of Ca
Ca

-dependent aggregation.

-independent aggregants did not cause shape change.

Shape change and aggregation had opposite temperature
dependencies; an acceleration of shape change occured when
temperature increased from 20 to 37 °C.

The conclusion was

that platelet shape change and platelet aggregation
represent different biochemical processes, and that shape
change is the event more closely related to platelet
activation.

Therefore, platelet shape change is potentially

the basis of a platelet activation assay that is more
meaningful than either aggregation or serotonin release.
The development of a PAF assay based on platelet shape
change has evolved during the course of this research
project.

This shape change assay may prove more useful than

the unreliable aggregation assay since it allows precise
testing of PAF and its photoaffinity-1abel1ing analogs which
will be used in the isolation and characterization of a PAF
platelet receptor .

2.
2.1.

Materials and Methods

S p p eia 1 Materials.

1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine (PAF)
was obtained from Sigma Chemical Co. (St. Louis, MO) at 99 %
purity.

1-O-alky1 - 2-hydroxyl-sn-glycero-3-phosphorylcholine

(lyso PAF) was supplied by Calbiochem Behring (San Diego,
CA) .

The other analogs of PAF were custom-synthesized by

Dr. Walter Shaw of Avanti Polar Lipids (Birmingham,
Alabama), and are listed as follows: 1-O-alky1-2-propanoy1sn-glycero-3-phosphoryIcholine (propanoyl PAF)

1-O-alky1-2-

butanoy1-sn-glycero-3-phosphoryIcholine (butanoyl PAF),
1-O-alky1-2-hex anoyl-sn-glycero-3-phosphoryIcholine (hexanoyl
PAF), and

1-oleoyl-2-acetyl-sn-glycero-3-phosphorylcholine

(oleoyl PAF).

Radiolabel1ed lyso PAF (1-0-[3H ]octadecyl-2-

hydroxy1-sn-glycero-3-phosphoryIcholine) was obtained from
Amersham (Arlington, IL).

The enzyme apyrase (E.C. 3.6.1.5),

phospholipase A2 (E.C. 3.1.1.4), and phospholipase C (Type 1)
(E.C. 3.1.4.3) were purchased from Sigma.

Phosgene was

obtained from Matheson Gas Company (Cucamonga, CA).

Benzy1 -

oxycarbonyIglycine, dicycl ohexy1carbodiimide (DCC), 8(diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride
(TMB-8) and 2 ,2 , 2-1rifluoroethy1 amine hydrochloride were
all obtained from Aldrich Chemical Co. (Milwaukee, WI).
Carrier-free H3 ^PO^ (specific activity 285 Ci/mg) was
purchased from ICN Chemical

(Irvine, CA).

and Radioisotope Division

All other chemicals were of reagent grade or
26
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of higher quality, especially organic solvents applied to
thin layer chromatography, and were obtained from commercial sources.
2.2.

Quantification of PAF and PAF analogs.

PAF is obtained from Sigma Chemical Co. (St. Louis, MO)
at very high purity as a solution (2mg/ml) in chloroform.
PAF has no unsaturated carbon chains, and has an ether
linkage which is significantly more stable than the ester
linkages found more commonly in phospholipids.

Therefore,

the most likely route of PAF decomposition is hydrolysis of
the ester linkage at positon 2 of the glycerol backbone.
The result of this hydrolysis is lyso PAF, whose presence in
preparations of PAF is readily determined by thin layer
chromatography.

It may be eliminated by preparative versions

of that technique,

The hydrolysis of PAF to lyso PAF in

chloroform solutions stored in the freezer at -20 °C occurs
at a rate of approximately 1% per month,

This

consideration, along with the availability of PAF of known
molecular weight with purity of 99%, means that PAF can be
quantitated routinely by phosphorus analysis if used within
two months of preparation.

Less stable PAF analogs,

supplied also at high purity in chloroform, can similarly be
assayed by phosphorus analysis when used immediately, or be
subjected to more elaborate schemes of analysis and/or
purification when stored for long periods of time.

For the
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purposes of this stage of the project, PAF and its analogs
were quantified by phosphorus analysis.
2.2.1.

Phosphorus Analysis.

The technique involved the spectrophotometric
determination of a phosphomolybdate complex according to
Long and Yardley (1970).

The analysis was carried out in

acid-washed glassware, free of detergent.

Standards were

prepared from potassium dihydrogen phosphate that had been
heated in an oven at 110 °C prior to weighing so as to
insure its anhydrous state.

The reagents used were 1) 10%

aqueous ammonium molybdate, 2) isobutanol : benzene, 1:1
v/v., 3) ethanol-su1 furic acid prepared by adding
concentrated sulfuric acid (8 ml) to absolute ethanol (242
ml) and mixing, 4) stannous chloride stock solution,
prepared by dissolving stannous chloride dihydrate (10 g) in
concentrated HC1 (25 ml), 5) stannous chloride reagent,
prepared by first diluting 2.5 ml of concentrated sulfuric
acid to 100 ml with distilled water and mixing, then adding
stannous choride stock solution (0.5 ml) after discarding an
equal volume of the sulfuric acid solution.
The procedure was as follows: 100 pi aqueous samples of
the phosphorus standards and unknowns were delivered to
individual 12 ml conical graduated glass centrifuge tubes,
followed by 0.9 ml of concentrated perchloric acid (70 - 72%).
These tubes were capped with glass marbles, and perchloric
acid digestion was allowed to proceed for 30 minutes in a
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preequilibrated sand bath (170 °C) under the hood.

After

cooling, marble caps were washed into the tubes and the
volumes adjusted to 3.5 ml with distilled water,

Ten

percent aqueous ammonium molybdate reagent (0.5 ml) was
added, followed by isobutanol-benzene (1.5 ml),

Ther eaf ter,

the tubes were rubber-stoppered , and the phosphomolybdate
complex extracted by vigorous shaking for 55 seconds.
Emulsions were broken by routine centrifugation at 200 x g
for 5 minutes .

The upper organic phase (1.0 ml) was saved,

and to this was added the ethanol-sulfuric acid reagent (1.0
The

ml), followed by stannous chloride reagent (0.2 ml),

tubes were immediately vortexed briefly and allowed to stand
covered for about 30 minutes after which the absorbance at
730 nm was measured with a Gilford spectrophotometer.
2.2.2.

Special

Tefthniqiif*

Another spectrophotometic approach has been developed in
this project for the specific quantification of PAF, which
can be employed when PAF has been stored for long periods of
time before use.

The basic idea rests on our observation

that phospholipase C from Clostridium perfringens will
cleave phosphory1choline from PAF but not lyso PAF.

In a

sample of PAF contaminated to any significant extent with
lyso PAF, phosporyIcholine released by the action of the
enzyme will come from PAF alone, and can be extracted and
quantified by phosphorus analysis.

A standard curve derived
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for the action of the enzyme under conditions of maximal
hydrolysis on standards of pure PAF can then be used to
quantify PAF in solution with lyso PAF.

The procedure

combines modifications of published approaches to
phospholipase C assay (Sigma Chemical Co., St. Louis, MO;
Blank et al. 1975).
Blank samples and standard PAF samples were delivered to
respective microcentrifuge tubes (Eppendorf, 1.5 ml) in
chloroform.

The chloroform was evaporated from each of the

samples by standard nitrogen flush techniques, and Tris-HCl
buffer (0.023 M, pH 7.3, 0.6 ml) was added, followed by
calcium chloride (210 mg/ml, 0.1 ml),

The mixtures were

then sonicated for 20 minutes in a bath sonicator at 0 °C to
disperse the lipids.

Phospholipase C was reconstituted to

100 units/ml in sodium acetate buffer (0.01 M, pH 6.0), and
87 pi of this solution was added to each sonicated sample
immediately after sonication.

The reaction was allowed to

proceed with continuous shaking in a mechanical apparatus for
10 hours at room temperature.
Subsequently, albumin (5% solution, 0.1 ml) and
perchloric acid (10% solution, 0.5 ml) were added.

Mixing by

inversion was followed by centrifugation (6000 x g, 30 min)
at 4 °C. The supernatants were saved in respectively labelled
microtubes, then filtered by ultrafiltration (Amicon PM 10
filters; Millipore Swinnex-25 unit) using 6 cc syringes.
The filtrates (0.7 ml) were pipetted into glass centrifuge
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tubes for phosphorus analysis.

The aqueous medium was

evaporated by nitrogen flush while the tubes were in an oil
bath at 98 °C.

Evaporation was allowed to continue until the

volume of solution remaining in each was slightly less than
0.1 ml, at which time the tubes were cooled and the volumes
adjusted to 0.1 ml with distilled water.

Phophorus analysis

was then performed as described above, beginning with the
addition of perchloric acid to the samples.
2.3.

Thin Layer Chromatography.

Standard procedural techniques were applied, utilizing
commercially supplied silica gel TLC plates (silica gel H,
i.e.

without calcium sulphate as binder; 0.25 mm layer

thickness).

The plates were spotted with sample volumes

ranging from 2 to 3 pi.

Before spotting, the plates were

activated by heating at 110 °C for 20 minutes, then allowed
to cool in a a dessicator containing Drierite and a
hydration indicator.

Solvent systems for TLC were allowed a

preequilibration of at least one hour in filter-paper lined
chambers. The two solvent systems used to separate PAF and
lyso PAF were 1) chloroform : methanol : water (65 : 25 : 4,
v/v/v), and 2) chloroform : acetone : methanol : acetic acid
: water (30 : 40 : 10 : 10 : 5, v/v/v/v/v).

For the

separation of a mixture of phospholipids by head group,
including phosphatidic acid, a solvent system recommended by
Supelco, Inc., (Bellefonte, PA) was the best tested:
chloroform : methanol : water : ammonium hydroxide, (65 : 25
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: 4 : 2, v/v/v/v) .
Detection of phospholipids on TLC was routinely
accomplished with a destructive charring procedure, but
occasionally by the nondestructive technique of spraying with
dichlorofluoroscein (0.05% in 50% ethanol) and viewing under
ultraviolet light.

The former technique involved first

spraying the plate to wetness with an ammonium sulphate
reagent (prepared by dissolving ammonium sulphate (20 g) in
100 ml distilled water followed by the addition of
concentrated sulphuric acid (4 ml)), then heating the
chromatogram on the surface of a hot plate (approximately
150 °C) for about 15 minutes (Ziminski and Borowski
2.4.

1966).

Co llf>etion of Blood fr om S h p p p

Western ewes of 80

100 lbs in weight were obtained

from Bennet Research Laboratories.

A catheter was placed

surgically in the femoral artery of the sheep and channeled
to a velcro-sealed cloth bag where a two-way valve was
attached (Perinatal Biology Laboratory, Loma Linda University
Medical Center).

The sheep was allowed one week of

recovery, during which it received daily injections (1.5 ml)
of Combi otic (a formulation of antibiotic containing
penicillin G and streptomycin).

The animal was maintained

under normal feeding conditions in the Animal Care Facility
in Risley Hall.

The catheter was maintained by daily

flushing with normal saline and replacement with heparin.

33

When blood was withdrawn for experiments, the first 10 ml
was discarded.

Aliquots (8 ml) were then drawn and slowly

added to silicon-coated, 10 ml vacutainer tubes containing
3.8% citrate (0.9 ml).

The vacutainer tubes were stoppered

and inverted gently for mixing.

The anticoagulated blood

was used immediately in the preparation of platelets for
study.
2.5.

Prpparfltion of Platfilfit Rinh Plasma

(PRP).

When testing was to be carried out on platelets in
plasma, 8 ml of blood was collected and processed,

Platelet

rich plasma (PRP) was prepared by centrifuging whole blood
at 230 x g, 15 min, to sediment red and white blood cells.
The supernatant, PRP, usually 2

3 ml in volume, was then

transferred to silicon-coated 15 ml polycarbonate centrifuge
tubes, and the cellular layer to three plastic microtubes
(1.5 ml) for the preparation of platelet poor plasma (PPP).
PPP was collected as the supernatant after these tubes had
been centrifuged at 12000 x g, 1 min.

While PPP was being

prepared, the platelet concentration in PRP was determined
with the Thrombocounter C (Coulter Electronics Inc., Hialeah,
FL) .

PRP was subsequently diluted with PPP to a

concentration of approximately 450,000 p1 at elets/p1 •

The

final preparation of PRP was then incubated at 37 °C and
supplied the aliquots used in subsequent platelet testing.
2.6.

Dptprmination of Platplfit Cnncentrfltions
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Platelet counts were measured with the Thrombocounter C
obtained from the Hematology Research Laboratory of Loma
Linda University Medical Center (LLUMC).

The procedure

involved pipetting 6.6 pi of the platelet suspension to a
thrombocounting vial containing 20 ml of Isoton (a blood
counting solution supplied by Fisher Scientific, Tustin,
CA) .

The sample was mixed and positioned for automatic

counting.

The numerical display was converted to actual

counts using a table provided with the instrument.

The

thrombocounter was calibrated periodically from the results
of a microscopic count performed with a hemacytometer using
a phase-contrast microscope.
2.7.

Preparation of Washed Platelets

The procedure for the preparation of suspensions of
washed sheep platelets combines features of Ardlie’s group's
methods for human, rabbit and pig platelets (Ardlie et al.,
1970; Mustard et al., 1972) with the density gradient
centrifugation technique of Ganguly and Sonnichsen (Ganguly
and Sonnichsen, 1973) and the use of apyrase as described by
Patscheke and Worner (Patscheke and Worner, 1978).
TVvo modified Tyrodes solutions were prepared with final
osmolality similar to that of sheep plasma,

These were the

washing solution (WS) and the final suspension medium (FSM).
WS was made up of sodium chloride (8.5 g), potassium chloride
(0.2 g), magnesium chloride hexahydrate (0.2 g), sodium
dihydrogen phohphate (0.05 g) , sodium bicarbonate (1.0 g),
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glucose (1.0 g)

and EGTA (0.076 g) in 1 liter of distilled

water, adjusted to pH 6.5 with 2N HC1.

FSM contained sodium

chloride (34 g), potassium chloride (0.8 g), magnesium
hexahydrate (0.8 g)

sodium dihydrogen phosphate (0.2 g),

sodium bicarbonate (4.0 g), and glucose (4.0 g) in 4 liters
of distilled water, adjusted to pH 7.3 with 2N HC1.

Final

suspension medium differed from WS by not containing EGTA,
and was buffered at a higher pH.
Metrizoate density gradient centrifugation was performed
sequentially in three silicon-coated, 50 ml, polycarbonate
centrifuge tubes containing 10 ml of a metrizoate solution
(32% metrizoic acid : water, 7 : 3, v/v).

PRP of count

greater than 800,000 per pi (30 ml) was layered on top of the
metrizoate in one of the tubes in which apyrase (250 pi of a
40 mg/ml solution in normal saline) had been mixed
immediately before.

A region of gradient (0.5 to 0.75 cm)

was created at the interface by stirring, and the tube was
centrifuged at 960 x g, 15 min, at room temperature,

The

platelet layer, near the bottom of the gradient, was removed
(5 ml) and gently dispersed to a total volume of 30 ml in WS
containing apyrase at a concentration of 1.0 mg/ml.

Density

gradient centrifugation was performed as before in
apyrase-metrizoate, and then a third time.

After the third

centrifugation the platelets were suspended to a total
volume of 10 ml in FSM containing apyrase at a concentration
of 1.0 mg/ml.

The final suspension was dialyzed against FSM
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(4 liters) for one hour to remove metrizoate. "Platelet poor
wash", prepared as the supernatant of an aliquot of washed
platelets centrifuged 12000 x g, 1 min, was used to dilute
the washed platelets to a final concentration of about
450,000 per pi.

Platelet testing was performed on this

final suspension of washed platelets at once.

2.8.

Aggrpgfltinn Assay.

Platelet aggregation was measured turbidimetrically
(Born, 1962) using a Chronolog aggregometer (Model 500 VS).
Light transmission changes of PRP (0.5 ml diluted 1:1 with
normal saline) in a silicon-coated cuvette were monitored
relative to a blank containing an identical dilution of PPP.
Tests were performed at a temperature of 37 °Cwith stirring
at a rate of 700 rpm.

The test cuvette containing the

sample was preincubated with stirring for 3 minutes followed
by the addition of the stimulant (5 pi) using a Hamilton
syringe.

The subsequent changes in light transmission

through the sample were recorded with a two-channel Linear
chart recorder.

The aggregation pattern was allowed to

develop for at least four minutes or until a clear maximum
was observed.

All tests were completed within 1.5 hr of

blood collection.

When inhibitors were studied they were

added in a 5 pi solution with a separate syringe 2.5 minutes
before the stimulant.
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2.9.

Measurement r> f ATP RpIpasp.

The Chronolog aggregometer is designed to measure ATP
release at the same time as platelet aggregation.

Through

the luminescence channel, light emission by a
luciferase-luciferin system is monitored, and is recorded by
the second channel of the recorder.

When ATP release was to

be measured, 0.1 ml of the PRP-diluting solvent was replaced
with 0.1 ml of luciferin-luciferase (40 mg/ml solution in
distilled water).

In other respects the test was run

exactly as in the absence of luciferin-luciferase, except
that a volume (2-4 pi) of ATP solution (0.04 mM) was added
at the end of the test as a means of calibrating the ATP
response.

2.10.

Peterminfltinn nf Sprotnnin RpIppsp.

Serotonin release was examined by measuring the decrease
in endogenous platelet serotonin.

Platelet pellets were

prepared by centrifugation (12000 x g, 1 min) of platelet
test samples before and after specific tests. The
supernatants were removed immediately, discarded, and the
platelet pellets stored in the microcentrifuge tubes at -70

°C.

Serotonin analysis was performed on the frozen pellets

approximately one month later using a fluorescence assay
(Vatassery et al. , 1981). Ascorbic acid was used in this
assay to stabilize serotonin.
Standard serotonin solutions were prepared in ascorbic
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acid solution (5 g/liter), and 1.0 ml of each was delivered
to plastic microcentrifuge tubes (1.5 ml),

Otherwis e,

platelet pellets in similar tubes were allowed to stand at
room temperature under ascorbic acid (1.0 ml) for 45 min to
thaw.

The contents of the microtube were frozen rapidly in

a dry ice-acetone bath and then thawed slowly at room
temperature.

This was followed by sonication with the

microtip of a Heat Systems Sonifier (Model W-225R) at 20%
maximum output for 15 seconds.
regimen was repeated twice.

The freeze-thaw sonication

Then, an aliquot (0.5 ml) of

the sonicated sample was transferred to a new microtube
containing absolute ethanol (1.0 ml), which enhances the
fluorescence of serotonin under these conditions.

The

mixture was then vortexed vigorously and centrifuged in the
cold room (6500 x g, 25 minutes).

An aliquot (1.0ml) of

the supernatant was transferred to a small test tube.

Ice

cold concentrated HC1 (0.6 ml) was added, and the
fluorescence at 540 nm with excitation at 295 nm was
measured in the Spex Fluorolog.

Endogenous serotonin

content of the unknowns was determined from the standard
curve.
2.11 .

Shap£_Cliaiig£_Aaalys.is._Qi_EAE
Development of this technique was prompted by

unreliability of the aggregation assay under the given
conditions, as well as an interest in developing a bioassay
for functional correlation with PAF binding.

The phenomenon
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on which the assay is based is the observation that light
transmission of a stirred sample of discoid platelets, but
not spheroid platelets, changes when stirring is stopped.
This change provides a measure of the proportion of the
collection of platelets that is discoid.

There is evidence

that ADP is released into the medium as platelets are
prepared, and this is likely to cause platelets to change
shape during preparation.
scavenge ADP.

Apyrase is therefore included to

A calcium ion chelator is provided in excess

to minimize the possibility of aggregation contributing to
the changes observed.
Apyrase (0.060 ml; 40 mg/ml in normal saline) was added
to the anticoagulant (0.9 ml citrate; 3.8%) in which the
blood was collected.

PRP was prepared in the usual manner.

The sample to be tested was diluted with 3.8% citrate instead
of normal saline, then preincubated for the usual period of
time but with a stirring rate of 200 rpm.

Then the stirrer

was turned off, the recorder pen allowed to stabilize,
followed by restarting of the stirrer at which time the
upward deflection of the pen to its near original position
was noted as the "control deflection".

Within 20 to 30 seconds

of restarting the stirrer (chart speed = 2 cm/min), the stimulus
was added. The stirrer was then turned off immediately (i.e.
within 3 of 4 seconds of stimulus addition), to be turned on
90 seconds later, at which time the movement of the pen was
noted as the "test deflection".

Preliminary studies led to
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the choice of the specific time interval between addition of
stimulus and test deflection.

A shape change parameter

(SCP) was calculated as j^l - (test deflection / control
deflection)] .

This procedure will be referred to as the SCP

Assay.
2.12.

Phosphatidio Aoid Formation

in PRP

The method was modelled after published procedures
for the estimation of phosphatidic acid formation in washed
platelets (Lapetina and Cuatrecasas, 1979).

The presence of

plasma in the samples of this project required modifications
of the published procedure.

A 3.1 ml preparation of PRP was
3 2 P04 (0.660 mCi in 86
combined with an aqueous solution of
pi) and incubated at 37 °C for 2 hrs.

Immediately after

incubation, an aliquot was tested with 5 pi distilled water
as a source of control values in the assays,

Within fif teen

minutes, another aliquot was taken and tested with PAF.
Immediately after each test, six aliquots (0.1 ml) were
delivered to labelled microcentrifuge tubes containing 0.374
ml of the solvent system chloroform : methanol, 1 : 2 v/v,

then vortexed vigorously to stop the reaction.

After all 12

tubes had been assembled, chloroform (0.125 ml) was added
with vortexing for fifteen seconds, followed by distilled
water (0.125 ml) and vortexing as before,

The contents of

each tube were subjected to centrifugal microfiltration in
MF-1 units with polytetraf1uoroethy11 aminate filters of 0.2
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pm pores (equipment supplied by Cole Scientific, Calabasas,
CA), 150 x g for 5 minutes.

These hydrophobic filters

almost totally excluded the aqueous phase and the
interfacial protein which it contained.

The filtrate,

organic phase, was freed of any remaining aqueous phase
(upper layer) using a Pasteur pipette, and evaporated
completely under nitrogen.

The residue was taken up in 20

Ml of TLC spotting solvent (chloroform : methanol, 2:1,
v/v).
A TLC plate was spotted left to right with a single spot
for each of the twelve samples such that the left half of the
20 x 20 cm plate contained the extracts from the blank
shape change test.

The spotted plate was developed in a

solvent system which separated phosphatidic acid from other
phopholipids in preliminary studies. Phospholipid spots
containing 3 2 P were detected by exposure of the developed
plate to X-ray film (Agfagaverte, LLUMC) for three weeks.
The spots on the developed X-ray film were quantified by
densitometric analysis using the Gel Scan program of the
Beckman DU-8 spectrophotometer.

Since the width of the

spots was greater than the length of the scanning slit, an
apparatus was designed to allow the scanning of the spot in
precise nonoverlapping sections.

This procedure was

referred to as Multiple Adjacent Scanning.

The computer

calculated the area of each peak, scanned according to the
baseline specifications that were entered individually.
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Finally, the areas of peaks generated for the sections of any
single spot were summed for a relative estimate of the amount
of labelled material in the spot.

3.
3.1.

Results

CQQfi£aiiiaiiQasL_Qi_EAE_and_iia_AaalQgs
PAF and PAF analogs were quantified by phosphorus

analysis, the standard curve for which is shown in Figure 1.
The phosphorus content of specified aliquots of stock
solutions of the PAF analogs was determined from the
standard curve and used, along with the molecular weights,
to determine concentrations (Table 1).

The concentrations

arrived at in this manner were very close to the values
claimed by the suppliers.

Figure 2 is a standard curve for

the second technique developed for the quantification of PAF.
3.2.

Elai£l£i_Aggr.figaiiQQ_l£aiiag
The effective concentrations of the various stimuli were

first determined by the aggregation assay from which four
parameters were measured for comparison with the results of
the new assay.

The typical aggregation profile begins with

an oscillating signal with stirring before the addition of
stimulus, followed by an immediate decrease in light
transmission upon adding the stimulus, and a subsequent
increase in light transmission accompanied by growing
oscillations as the platelets aggregate (Figure 3.).
Features of the aggregation profile were measured in
recorder chart units as follows.

First, the initial

decrease in light transmission was noted as an indicator of
the disc-sphere transformation during platelet activation.
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Figure 1.
Phosphorus

Standard Curve of Phosphorus Analysis.

containing samples were assayed in 100 Ml

aliquots, and the concentrations
phosphorus/100 pi.

expressed as ug

Each point on the graph represents the

result of a single test.
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Table 1
Concentration of PAF and PAF Analogs
from Phosphorus Analysis

PAF
Analog

Molecular
Weight

Assayed
Phosphorus
Concentration
yg/tube

Sample
Volume
hi

Concentration
mg/ml

18.0

2.0

PAF

558

2.02

Propanoyl PAF

572

2.13

7.2

5.4

Butanoyl PAF

586

2.57

7.2

6.7

Hexanoyl PAF

614

2.35

7.2

6.5

Oleoyl PAF

563

2.15

3.6

10.8

Phosphorus was estimated with the standard curve (Figure 1). Each
value reported is the mean of two results. Volumes of the stock
solutions of the lipids in chloroform were sampled for assay so that
the concentration of phosphorus would be about 2 yg/100 yl. The
concentrations of PAF and PAF analaogs are reported for the stock
solutions. Differences in dilution and in molecular weights were
taken into consideration for the calculation of phospholipid con
centrations of the stock solutions.
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Figure 2.
and Phosphorus

Quantification of PAF by combined Enzymatic
analysis.

PhosphoryIcholine was hydrolyzed

from PAF by phospholipase C,
analysis.

then detected by phosphorus

Each point on this standard curve

of two values .

is the average
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Figure 3.
the addition

PRP Aggregation Profile.
of PAF (5 Ml)*

the addition of PAF

The arrow indicates

The oscillating signal before

accompanies stirring of the platelet

suspension at 700 rpm during the 3

min preincubation at 37 °C.
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Second, the maximum light transmission change observed was
expressed as a percentage of the calibrated full scale
deflection and referred to as nBm 96 Max".

Third, "B4 96 Max"

was calculated from the light transmission change at four
minutes after the addition of stimulant.

The steepest slope

of the portion of the aggregation profile representing
platelet aggregation was measured in degrees as "Slope'1.
Preliminary observations showed that the aggregation
profile of PRP in response to a single concentration of PAF
changed significantly with time after blood collection.

To

monitor this problem, a protocol was adopted whereby each
concentration of stimulant was tested repeatedly, usually
three times, with succesive aliquots of a single preparation
of PRP.

The time after blood collection at which each test

began was noted.

Insets in Figure 4. illustrate the changes

in the profile with time for stimulation by 4.3 nM PAF and
represent similar apparent decays in responsiveness of
platelets observed for other concentrations of PAF.
A standard time of approximately sixty minutes after
blood collection was selected for comparing the effects of
different concentrations of PAF.

The values arrived at in

this manner are summarized in Table 2.

The initial decrease

in light transmission was not dependent on the concentration
of PAF.

The other parameters correlated with the

concentration of PAF over the approximate range of two
orders of magnitude (from 1.1 nM to 69 nM).

This correlation
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Table 2
Aggregatory Response of PRP to PAF
PAF
Concentration
nM

Initial Change
in % Light
Transmission

69

-3.0

17

on
Slope,

0

B m % Max

B.4 % Max

82.4

63.0

60.8

-2.2

73.1

60.2

57.5

4.3

-3.0

65.5

35.0

34.3

1 .1

-3.4

32.4

3.0

2.4

Series of tests with each concentration of PAF were performed over a
period of less than 90 minutes on a single preparation (2.5 ml) of PRP.
The values of the parameters reported are single measurements from
tests started at about 60 mins after blood collection. Initial Change
in % Light Transmission was measured in recorder chart units.
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Figure 4.
SCP.

The

Time Dependent Changes in Aggregation and

aggregation and SCP tests were performed,

respectively, each with a single

preparation of PRP as soon

after blood collection as possible,

Aggregation profiles in

insets a), b) and c) are for tests started 50, 60
minutes after blood collection respectively.
profiles

and 70

SCP assay

d) , e) and f) represent tests of 55, 61, and 69

minutes after blood

collection respectively.

illustrates the stirring procedure of
concentration of PAF was 4.3 nM.

Inset e)

the SCP assay.

The
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Figure 5.

Dependence of Aggregation Parameters on PAF

Values of Slope and Bm % Max were taken
from Table 2. and plotted as a function of the final

Concentr ation .

concentration of PAF.

The

squares and stars represent

Slope and Bm % Max respectively.
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is graphically represented in Figure 5.

Lower

concentrations of PAF than those listed were capable of
causing the initial decrease in light transmission, but not
aggregation as signified by positive values of
3.3.

96 Max .

SCP Assay with PRP

The measurement of SCP is based on observations related
to morphological changes of platelets accompanying
activation.

Attempts here to define those changes using

electron microscopic techniques have not yet been
successful.

Some verification of the approach was sought in

an experiment designed to look for a relationship between
the number of presumably discoid platelets in plasma and the
control deflection.

Unstimulated platelets in PRP were

tested after dilution to known concentrations with PPP; the
results are summarized in Figure 6.

The number of

platelets, on the abscissa, is that suspended in PRP before
dilution with 3.8% citrate.

It was not necessary to correct

results for the absorbance differences of the suspensions of
varying platelet concentrations since the chart scale was
set and calibrated once for the whole sequence of tests.
Above 450,000 p1 atelets/u1, the value of the control
deflection in SCP determination decreased with increasing
numbers of unstimulated (presumably discoid) platelets.
Below 450,000 piatelets/u1 , there was a direct correlation
between the number of unstimulated platelets and the
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Figure 6.
Concentration of

Control Deflection relative to the
Unstimulated Platelets.

into aliquots and diluted with
concentrations.

PRP was divided

PPP to the indicated

The results represent tests of one

sample

of each concentration, in which the SCP assay technique was
taken

only as far as the control deflection.
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magnitude of the control deflection.

SCP was not determined

in these tests, but in subsequent experiments PRP was
prepared at concentrations between 400,000 and 450,000
piatelets/p1.
3.3.1 .

Relationship tn Aggregation and other Assays

When SCP was measured as described earlier, its value
did not change greatly with time, in contrast to the
aggregation profile.

This is seen in a comparison of the

SCP assay profile and the aggregation profile for
stimulation with 4.3 nM PAF at a series of equivalent times
after blood collection (Figure 4).

The effect of time of

test after blood collection on Elm 96 Max and on SCP was
determined statistically, adjusting for PAF concentration
There was a significant decrease in Bm %
Max of 8 % per unit increase in time (p < 0.05). There was
(Tables 3 and 4) .

no significant change in SCP with time (p > 0.05).
SCP assay in PRP showed a marked concentration
dependence for concentrations of PAF ranging from 0.033 nM
to 69 nM, the highest concentration tested (Table 4 and
Figure 7).

This concentration range included the levels of

PAF that were able to cause aggregation.

Further, although

response appeared to be near saturation in both assays with
69 nM PAF, the SCP assay was sensitive to concentrations of
PAF approximately thirty times smaller than the lowest
concentration of PAF (1.1 nM) effective in aggregation as
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Table 3
B m % Max with PAF Concentration and Time
PAF Concentration (nM)
17

4.3

1 .1

Time

B

m

% Max

45

67.1

55

63.8

65

56.6

50

48.0

60

35.0

70

16.3

50

8.4

60

3.0

70

1 .8

Each concentration of PAF was tested with a different preparation of
PRP. Time is in minutes after blood collection.
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Table 4
PAF Concentration and SCP in PRP
Concentration of PAF
nM

Trial

Time

SCP

69.0

1

48

0.97

2

54

0.96

3

60

0.85

1

46

0.86

2

52

0.94

3

59

0.88

1

55

0.74

2

61

0.74

3

69

0.75

1

46

0.64

2

53

0.62

3

62

0.54

1

65

0.32

2

72

0.48

3

77

0.49

0.13

1

83

0.32

0.033

1

96

0.06

2

103

0.12

17.0

4.3

1 .1

0.27

Time is in minutes after blood collection.

SCP (Average)

0.93

0.89

0.74

0.60

0.43

0.32

0.09
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Figure 7 .
Con t r ol

deflection and test deflection were measured and SCP

calculated as
and 11.

SCP as a Function of PAF Concentration.

described. The values were taken from Tables 4

Data points for

all the trials with each

concentration of PAF were plotted but the curves
according to the averages.

were drawn

Squares and stars indicate results

from PRP and Washed Platelets respectively.
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SCP

0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0-90 1.00
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measured by B

% Max .

Partial correlation between SCP or Bm % Max and the
logarithim of PAF concentration, holding time fixed, was
determined.

The partial correlation coefficients for Bm %

Max and for SCP were 0.96 and 0.91 respectively.

A

comparison of these coefficients was made via the Fisher z
transformation.

None of the partial correlation

coefficients were significantly different from each other.
However, the fact that correlation coefficients for the SCP
assay were high means that the assay may be very useful.
The question of the usefulness of the SCP assay as an
alternative to aggregation in measuring platelet activation
was taken beyond a demonstration of sensitivity to
concentrations of PAF effective in platelet aggregation.
Correlations with other measures of platelet activation such
as serotonin release were sought.

Figure 8 shows the

emission spectrum of serotonin in response to excitation at
295 nm.

Serotonin extracted from platelets also showed the

characteristic fluorescence maximum at 540 nm.

The

relationship between the concentration of standard serotonin
and the fluorescence intensity at 540 nm was linear (Figure
9) .

This standard curve was used in estimating serotonin

released from platelets in PRP under the conditions of
aggregation (Table 5) and the SCP assay.

PAF

concentration-dependent serotonin release was detected
during aggregation, but only for PAF concentrations of 4.3
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Figure 8.
spectrum of

Fluorescence Spectrum of Serotonin.

A. The

standard serotonin for excitation at 295 nm

shows the characteristic

maximum at 540 nm.

B. The

fluorescence spectrum of serotonin extracted from platelets.
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Figure 9.
f luorescence

Standard Curve of Serotonin Analysis.

The

(540 nm) of standard solutions of serotonin in

response to excitation at

295 nm.

Three determinations

were made for each concentration of serotonin.
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Table 5
Serotonin Release during Aggregation Assay
or SCP Assay
RAF Concentration
nM

Serotonin Release,
yg/yl PRP

69.0

0.41

17.0

0.26

4.3

0.10

1 .1

0.09

Serotonin release in PRP was determined with the standard curve
in Figure 9* The fluorescence representing release was the dif
ference in fluorescence of the PAF-stimulated sample and that of
unstimulated platelets sampled at the same time after blood
collection. Each value of serotonin release is the average of
two determinations, and is standardized to a test with PRP of
initial platelet concentration of 450,000 platelets/yl.
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nM or greater.

PAF at concentrations of 1.1 nM and 4.3 nM

yielded the same basal amount of serotonin, representing the
lowest level of serotonin release.

Serotonin release during

the SCP assay was minimal and independent of the
concentration of PAF over the range tested (1.1 nM to 17nM).
This was due to the absence of extracellular Ca 2 + under the
SCP assay conditions but the results were identical to the
smallest values of serotonin observed with aggregation.
Although serotonin release under SCP assay conditions
was negligible, phosphatidic acid formation could be
detected.

The average intensity of the radiolabel1ed

phosphatidic acid spots in six tests stimulated with water
was expressed as 100%.

The value of SCP measured was zero.

Platelets in PRP stimulated with PAF at a concentration of
69 nM yielded an average value of 150% phosphatidic acid
spot intensity relative to control.

The corresponding value

of SCP was 1.10.
ATP release from platelets in PRP was measured under the
conditions of the SCP assay.

Superimposed on the profile of

the SCP assay was that of ATP release shown in Figure 10.
ATP release was proportional to the concentration of PAF.
It also correlated with the values of SCP arrived at, such
that as PAF concentration was varied from 1.1 nM to 17 nM
both SCP and ATP release increased markedly, with the latter
changing over two orders of magnitude (Table 6).
release was apparently not stimulated by PAF of

ATP
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Figure 10.
pattern of the

ATP Release Test Profile.

This typical

output of the luminescence channel of the

aggregometer was recorded

simultaneously with the SCP assay.

The change in signal that precedes the

addition of a

stimulus is due to the automatic closure of the luminescence
channel when the test chamber is opened.
solution for

The standard ATP

calibration was added immediately after the

test deflection of the SCP

assay was complete.
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Table 6
Simultaneous SCP Assay and ATP Release with
Various PAF Concentrations
PAF Concentration
nM

SCP

ATP Release, ymoles

17.0

0.90

1.9 x 10

4.3

0.80

3.7 x 10"5

1 .1

0.52

2.4 x 10 -6

0.13

0.31

0.00

-4

ATP Release and SCP were measured simultaneously in PRP. Each value
recorded is the average of two measurements except for PAF of 1.3 x
10
nM. For this concentration of PAF, even though the gain of the
luminescence channel was adjusted to a level forty times greater than
in the other tests, no pen deflection was observed.
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concentration 0.13 nM and could not be detected even when the
instrument was set at its highest gain,

At this same

concentration of PAF, however, a significant value of SCP
was observed, suggesting a greater sensitivity of the latter
to PAF.
3.3.2.

Rffeet of Modulators

The effects of modulators of platelet activation on SCP
were examined to establish the relatedness of SCP measurement
to processes associated with platelet aggregation and
r el ease.

The first step was to define the effectiveness of

the inhibitors towards the aggregation of sheep platelets
stimulated by PAF.

The decay with time of the

responsiveness of platelets in aggregation made it difficult
to identify the changes that were due to the presence of the
modu1ators .
Table 7.

The results for 4.3 nM PAF are summarized in

The time of the first control test was 46 minutes

but another control was run approximately 30 minutes later,
within the the total time of 90 minutes allowed for tests
following blood collection.

During this period of time the

aggregation parameters noticeably diminished.
Inhibition by TMB-8 (62 pM) was the only unequivocal
result of these tests.

Indomethacin was not expected to have

an effect but the apparent lability of the platelets did not
allow a definite answer.

Surprisingly, the effect of added

prostacyclin was not strong enough to be stated with
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certainty.

One probable explanation of this result was the

lability of prostacyclin in aqueous solution.

When first

received, prostacyclin was dissolved in an aprotic organic
solvent as a safeguard against hydrolysis.

Subsequently,

following evaporation of the solvent, it was dissolved in
bovine serum albumin solution (0.25%) for testing.
Preliminary testing showed levels of prostacyclin activity
much greater than seen in these results which represent
tests performed after two weeks of storing the organic
solution at -20 °C.
SCP appeared to be inhibited in a concentration
dependendent manner by the same preparation of prostacyclin
used in the aggregation studies (Table 7).

TMB-8 also

reduced SCP in proportion to its concentration, but this
effect was not as large as upon aggregation where the
parameters Slope, Bm % Max and B4 % Max were zero or less
(Table 7).

Although aggregation was totally inhibited by 62

(jM TVIB-S, the usual

initial decrease in light transmission,

indicative of the disc-sphere transformation, could still be
observed.

Indomethacin (20 pM) seemed to have only a small

effect on SCP.
Control and test values of SCP in these studies were

compared using a t-test.

Because of the small sample size

for each inhibition result in Table 7, a common variance for
these tests was estimated by pooling variances from all the
inhibition experiments with those from previous measurements
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of SCP (Table 4).

The only significant reduction of SCP was

that due to 62 pM TMB-S (p < 0.01).

Apparent inhibition by

indomethacin (4.8 %) was not significant (p > 0.05).
The experiments with prostacyclin were repeated with a
new sample of the prostaglandin reconstituted in ice-cold
Tris buffer (0.05 M, pH 9.35).

Unpublished findings,

relayed by Sigma Chemical Co. (St. Louis, MO) upon request,
indicated that prostacyclin was resistant to hydrolysis
under these conditions for two days.

All tests with this

prostacyclin were completed within 6 hours of preparation of
the solution.

It was found that prostacyclin at a

concentration of 0.075 pM inhibited the Slope and B m % Max
aggregation responses to 17 nM PAF by 87% and 100%
respectively.

A concentration of 0.60 pM inhibited both of

these parameters by 100%.
Prostacyclin concentration was varied between 0.60 pM
and 0.004 pM, and the effect on the SCP and ATP release
responses of platelets in PRP to 17 nM PAF was monitored.
Concentration dependent inhibition of SCP occurred over the
entire range of prostacyclin concentration tested (Table 8).
A 0.15 pM solution of prostacyclin inhibited SCP by 80.7% as
compared to 9.2% in earlier tests (Table 7).

ATP release

was also dependent on the concentration of prostacyclin but
was more sensitive than SCP.

ATP release was almost

completely inhibited by concentrations of prostacyclin
greater than 0.075 pM.

In contrast, concentration-dependent
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Table 8
Inhibition of ATP Release and
SCP by Prostacyclin

pgi2 Concentration
yM

% Inhibition of
SCP

% Inhibition of
ATP Release

0.60

91 .5

98.3

0.30

84.1

97.0

0.15

80.7

97.1

0.075

77.8

95.0

0.018

56.8

84.6

0.004

12.6

30.1

Inhibition by prostacyclin was observed in simultaneous assays of ATP
release and SCP in PRP stimulated with 17 nM PAF. Prostacyclin was
dissolved in ice-cold Tris buffer (0.05 M, pH 9.35), and was used
within 6 hrs of solution preparation. Four to six tests were run for
each blood collection, and each series of tests was begun with a
control test (without prostacyclin). Each value of inhibition is
the average of two results.
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inhibition of SCP could be seen up to 0.60 pM prostacyclin,
a concentration at which the inhibition of SCP was markedly
less than that of ATP release.
The partial corrrelation between the logarithim of PGI2
concentration and the logarithim of SCP or ATP release was
determined, adjusting for PRP preparation.

For ATP release,

a high correlation coefficient of 0.97 (p < 0.001) was found
over the full range of PGI2 concentrations.

Similarly, SCP

showed a high correlation coefficient (0.96, p < 0.001).
Thus, the inhibition results for ATP release as well as
SCP were significant.

To avoid the problem of having to

take the logarithim of zero concentration in this
statistical

analysis

0.00025 nM PGI2 was substituted as a

concentration that would not inhibit ATP release or SCP and
be equivalent
3.4.

to control values.

AciiYiiy_Qi_Syaili£iic_AafllQgs._Qi_EAE

The effects of several common analogs of PAF in
aggregation and SCP assay were measured.

Concentrations of

analogs which were capable of causing aggregation could also
be detected by the SCP assay (Table 9).

The concentration

of analogs necessary for effects measured by both
aggregation and SCP assay ranged from 4.3 nM to 1.3 x 105
nM.

Preliminary testing for pinpointing effective

concentrations of PAF analogs in the SCP assay showed that
the value of SCP was dependent on the concentration of the
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Table 9
Analogs of PAF in Aggregation and SCP Assays
PAF Analog

Concentration, yM

SCP

Lyso PAF

1.3 x 10 5

Hexanoyl PAF

7.0 x 10

Hexanoyl PAF

3.5 x 10

Propanoyl PAF

9.0

Propanoyl PAF

3.6 x 10

Butanoyl PAF

9.4 x 102

Butanoyl PAF

2.3 x 102

Oleoyl PAF

6.2 x 104

0.81

Oleoyl PAF

1.5 x 104

0.68

Oleoyl PAF

3.9 x 10

PAF

4.3

0.35

3
3

B

Number of

12.0

0.3

2

31 .9

3.6

1

0.21
0.72

1

%
m
Max

Slope, °

2
59.6

27. A

3
0.74

2
1

0.91
0.75

Tests

78.4

74.5

2

16.3

1 .8

1
2

80.0

76.5

2

69.3

66.0

2

52.0

18.1

2

Effective concentrations of each analog of PAF in PRP were determined
by screening a wide range of concentrations.
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analog.

This is illustrated in the SCP results for propanoyl

PAF and oleolyl PAF in Table 9.
The activity of PAF relative to the specific analogs of
PAF was calculated by first noting the equivalent
concentration of PAF necessary for the observed slope or SCP
value (from the relationships plotted for PRP in Figures 5
and 7) .

Relative activity was then expressed as the ratio

of the equivalent concentration of PAF and the effective
concentration of the analog.

The variables in this process

and the results are summarized in Table 10.

Generally, for

those analogs for which relative activity could be estimated,
larger values were found with the SCP measurement than with
the aggregation assay.

The only exception was propanoyl PAF

where the values found by the two methods were nearly
identical .

Estimates of relative activity from various

concentrations of an analog did not differ greatly,
especially when compared to the scale of difference between
different analogs.

An estimate of the activity of PAF

relative to lyso PAF could not be derived from Figure 5, but
the relative values of both the concentration of lyso PAF
and its slope effect show that it was the least active
analog in aggregation.

This is supported by the results of

the SCP assay.
The progression of activities was as expected from
published results of experiments with other animal systems,
i.e. propanoyl > butanoyl > oleoyl > hexanoyl > lyso PAF,

85

cx

ro

o

[iu

< eu

o

Cu O
00
Cm

ro

o

i
i

ro

c\i

ro

o

X

C\)

X

<r

LO

o

o

X

X

I
i

LO

to-

CO

O
>j

-p

i—i

>

ro

C

P> o

0

<

0
0

o

CO
bO
O

x:

0

o

U "H
-P
0
0 bO
> 0
•H 0
-P bD
0 bO
rH <C
0
0

O

o

'O

I
I

CM

o
LO
CM

ro

I
I

LO

<r
<r

I
I

TC

X

I
i

0

0 o
0 co
0 C
O
CO -H
0 0
0 0
0 0
C 0
•H C
CM

0

o

I
I

00

o

co

LO
tr-

o

o

i
I

CO
0)

CO

CM

o

o

o

LO
I
I

ro
o

>

0

ox

o
0
CX

o

MO
I
CO
LO

I
I

<r

ro

O

CO

CO
M0

o
CO

co
I
I

LO

00

ro

o
CM

o

>

0

o

0

b-

0 0

0
0
0

bO 0
C b£)
■H *(—i
C C |0
O ‘H

E C

0

•H
0
CJ

0
0

w cr

0

0
•H

C
O

o c

10

>1

E 0
o

O
vO

X0 0
0 0
0
0 >
0 •(—t
0

o
0

<0,

S-i 0

G

•H
0
0

o
O

0

0

H

-P

i—I <
JO 0

ro

00

0
0

aj

O E
0 o
u

0
G
«=C
0
•H
0
0

•

C i—I
O 0)
•H J-i
-P
U 0

0 x:

•H

•H

I 'H
Oj
i—I W
CD C
K O
•H
4J

2
0-

G
o
•H
0
0
0
0

0
O
I
I

o
co

G
0
o
c
o
o

CO

o

<r

o

<r

o

co
o

ro
o

LO

o

X

X

X

X

X

X

X

X

M0

<r

co

LO

0

LO

o

0

MO

0

0

0

u

0 TO C
OX 0 o
0 0 O
0
i—I 0
G 0 =X

o a 0

•H i—I
0 0 TO

0 o c

0

<=x

0
0
0

0
ex
0

0

<c

0
r—I
0
O
G
0
0

0

E

•H
0
00

o

TO 0 -H
0 0
W 0 G
0 0 O
XO TO -H
0
0 0 0
0 0 0
0 0 0
3 0 C
0 0

0
O
G
0
0

0

o

o

0

Sm
0

G
0

<x

0
0

0
O

c

0
0
0
CO

rH
0
O
CD

0
■=x
0

0

0

0

0

0
0
O

0

o

CD

10

o

CD
■---- i

o

0

<

o

o

c

0
X
CD
0

rH
0

o
c

0
X
CD

0
■=x
0

o
0
0
0

bO
0 W
0 0
b£) 3
bO
0 >)
0
E ‘H
O >
0 •!—(
0 0

0
>5
-0
•H
>
*H
0
0
0

o c

0 0 CD
CD
(D
0 CD 3
rH > 0
0 -H 0)
>00

86

Table 11
PAF Concentration and SCP
in Washed Platelets
Concentration of PAF
nM

Trial

Time

1

30

1 .08

2

38

1 .06

1

45

0.90

2

53

0.85

1

60

0.51

2

69

0.47

0.033

1

76

0.34

0.0085

1

87

0.10

2

94

0.13

17.0

SCP

SCP (Average)

1 .07

4.3

0.88

0.13

0.49

0.34

0.12

Tests were performed on a single preparation of platelets,
minutes after dialysis.

Time is in
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and was unambiguously shown by the results of the SCP assay.
SCP demonstrated greater sensitivity to the structural
differences between the analogs than did aggregation (Table
10), and this is most clearly seen in the comparison of
propanoyl PAF and butanoyl PAF.
3.5.

SCP Assay of Washed Platelets

Finally, SCP was measured for PAF acting on suspensions
of platelets washed by metrizoate density gradient
centrifugation.

A PAF concentration dependence quite

similar to that seen with PRP was found (Table 11 and Figure
7).

A high correlation coefficient of 0.96 was determined

as described for studies with PRP.
change in SCP with time.
curve (Figure 7)

There was no significant

The upward displacement of the

indicates a greater PAF sensitivity of

platelets in artificial media, which agrees with
observations of platelet aggregation by other researchers.
SCP-assayed activity was detected at a PAF concentration
(8.5 pM) about 4 times lower than studied in PRP.

4.
4.1 .

Discussion

The Study of Platelet Shape? Change

Platelets

support

a

host

of

activities:

adhesion,

aggregation, uptake and release of serotonin, release of
other substances, procoagulant activity, clot consolidation,
and roles

in

i n f 1 anunat ory and

immunological

reactions.

All of these functions require initiation of mechanisms
embodied in platelet activation.

PI atelet activation

appears always to be accompanied by early morphological
changes which may be prerequisite to the succession of
events following ligand-platelet interaction,

The

recognition that shape change of platelets is a necessary
prerequisite phenomenon occurring prior to their
participation in a number of important physiological
processes has provided impetus for the development of
improved assay techniques directed at this early event of
platelet activation.
Basic definitions in the study of platelet shape change
have been established with the technique of microscopy which
is the primary tool for obtaining morphological information.
In humans, 65% to 95% of the platelets in either whole blood
or citrated PRP are smooth, disc-shaped structures,

The

remaining fraction has been loosely referred to as spheroid
platelets, and the initial shape change of activation as

88
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Since some of the platelets in

disc-sphere transformation.

this fraction always have main bodies which are not
spherical, a more accurate and useful classification would
recognize structures termed discoechinocytes (DE) , and
spheroechinocytes (SE), in addition to the discocytes (D).
This classification is based on phase-contrast microscopy
where edge-on discocytes appear ellipsoid with a clear center
while face on discocytes appear circular with a dark center
(Frojmovic and Milton, 1982).

Spheroechinocytes appear

circular with a white center while discoechinocytes satisfy
none of these criteria.

Both of the latter types of

platelets are termed echinocytes because of the presence of
variously formed pseudopodia.

This scheme seeks to simplify

the complex array of morphological entities seen with the
microscope.
The turbidometric method now known as aggregometry,
because of its most common application in quantifying
platelet aggregation, was
O'Brien, 1962).

introduced in 1962 (Born, 1962;

It is classified as a rheooptical technique

because its basis is in the optical theory of light
transmission and light scattering as well as the theory of
stress

in fluid dynamics.

The stress introduced by stirring

a platelet suspension in vitro allows a limited
approximation of physiological platelet response.
Approaches combining the techniques of aggregometry and
microscopy have already provided significant information
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about the shape change of platelets upon activation.

Studies

of the time course of morphological alterations caused by ADP
indicate the progression D

DE

SE, and that platelet

aggregation occurs in a manner paralleling the time course of
formation of DE but with a requirement for other events
leading to the generation of sticky sites on the platelet
(Frojmovic and Milton, 1982).

Low concentrations of

thrombin, collagen and ADP result in the formation of DE with
long pseudopodia, while high concentrations are associated
with the production of SE with long pseudopodia (White,
1974).

Other platelet stimulants such as epinephrine can

have different effects on morphology (Patscheke and Worner,
1 978; White, 1 970 ) .

Platelet shape is sensitive to the type

of anticoagulant used; EDTA significantly affects platelet
shape (Zucker and Borelli, 1954).

The pattern of

morphological alteration seen with a particular physiological
platelet activator is also affected by variations in
temperature (Zucker and Borelli, 1954).
The initial decrease in percent light transmission (% T)
of the aggregation profile has been correlated with increases
in the proportion of echinocytes (Milton et al., 1980).
Maximal initial decreases in % T have been found with maximal
echinocyte formation which normally involves a final mixture
of DE and SE (Macmillan et al. , 1 965 ).

Some investigators

have examined the kinetics of the initial decrease in % T in
studying platelet activation.

More commonly, however, the
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magnitude of the initial decrease in % T has been
interpreted as reflecting the shape change of platelet
activation.

Such was the approach taken in the recent

demonstration of a correlation between the concentration of
PAF and the shape change of human platelets suspended in
artificial media (Lapetina and Siegel, 1983).

They observed

that the magnitude of the initial decrease in light
transmission changed as the concentration of PAF was
increased in steps of one order of magnitude between 0.1 nM
and 1.0 mM.

The observed trend of a larger initial decrease

in light transmission with an increase of PAF concentration
was not always clearcut.
Other measures of platelet shape change have come from
an exploration of less obvious features in the rheooptic
study of platelets.

Time-dependent variation in the flow of

the platelet suspending medium when stirred causes
alterations
oscillations

in platelet orientations, resulting in
in the mean scattering cross section of

particles in the light beam.

This is the basis of the

oscillations seen in the signal of the aggregation profile
before the aggregating agent is added.

As expected, this

effect is not associated with spherical particles such as
latex spheres (Frojmovic, 1975).

A maximal change in the

maximal oscillation amplitude occurs with the process of
complete sphering of disc-shaped erythrocytes and platelets.
Further, the fractional change is linearly related to the
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ratio of spheroid to discoid cells (Frojmovic, 1975).
Stirring provides yet another exploitable effect which
influences the pattern of the aggregation profile.

The rate

of stirring of platelet suspensions is an important factor
in aggregation but it is also a factor in determining the
actual value of transmission.

When the rate of stirring of

a suspension of asymmetric particles is varied, a biphasic
change in light transmission results.

In contrast,

spherical latex particles varying in size from 1 to 10
microns do not show any stirring-dependent changes in light
transmission (Frojmovic, 1975), regardless of polydispersity
in size or aggregation.

For asymmetric particles, a maximal

change is seen when an unstirred suspension is suddenly
stirred at a rate of 900 rpm or more (Frojmovic and
Panjwani, 1975; Frojmovic, 1975).

This last observation was

confirmed in 1976 by a number of investigators, one of whom
was the pioneer of the turbidometric approach (Latimer et
al. , 1 977 ) .
In studying PRP of rabbits, Latimer’s group observed a
25% increase in optical density when stirring at 900 rpm
was suddenly discontinued.

These investigators went a step

further to show that the effect of stirring was in agreement
with the theoretical predictions of light scattering
(Latimer et al. , 1 977 ). They also demonstrated that when a
high concentration of ADP was added to a stirred suspension
of platelets, after the addition of EGTA to prevent
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aggregation, a marked increase in extinction occurred to
levels approximating those found by turning off the stirrer
before stimulation.

Turning off the stirrer after this high

degree of stimulation did not cause extinction to increase.
These observations provided the basis for development of the
SCP assay described in this dissertation.
Latimer and colleagues suggested in 1976 that a
theoretical curve of relative extinction versus axial ratio,
such as the one they developed, could be used to assay the
shape of platelets (Latimer et al. , 1 977 ).

There is no

published record that this possibility has been explored.
4.2 .

SCP Assay Dpsign

The newly developed SCP assay was designed not only on
the basis of theoretical principle but it incorporates
information

from various other observations made in the

study of platelet shape change.

The signal from the

aggregometer has been amplified in a range of 5 - 10 fold
so as to maximize the changes associated with stirring and
nonstirring of a platelet suspension.
Among the effects that Born and his colleagues reported
in 1977 was the tendency of the platelets to change shape
with mere stirring over the period of the test (Latimer et
al., 1977).

The protocol of the SCP assay not only dictates

minimal stirring over the entire period of the test to
minimize possible artifacts related to platelet shape
instability but a control deflection measurement in each
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assay is also recorded.

No stirring actually occurs during

the response of the platelets to the stimulus.

This is in

contrast to the approach taken by Born’s group, where, in
looking at the effect of a single concentration of ADP

the

test response was obtained by turning off the stirrer
minutes after stimulus addition.

Also in contrast

to

other techniques, this method uses citrate as calcium
chelator, which avoids EDTA and its effects on platelet
shape.

At the concentration and volume employed, full

chelation of extracellular calcium is insured, and the
platelets reside in a hyperosmolar medium of approximately
320 mOsm.
The amplitude of the oscillatory signal that occurred
during stirring was found to vary directly with the rate of
stirring, but was compatible with subsequent measurement
when the PRP was stirred at 200 rpm.
oscillations

The problem of large

in the signal at the required level of

amplification was compounded by the presence of apyrase, a
very stable enzyme which scavenges ADP by its hydrolysis.
This enzyme had been used by Patscheke to preserve the
discoid shape of platelets during washing (Patscheke and
Worn er, 1 9 78).

Preliminary observations in our laboratory

showed that apyrase caused the appearance of greater initial
oscillations in PRP and allowed their maintenance for longer
periods of platelet storage time.

The decision to include

apyrase was based on the fact that activation of platelets
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by PAF in other biological systems does not require ADP, but
this limits the SCP assay to pathways independent of
extracellular ADP.
Patscheke reported that shape change effects observed in
the aggregometer were best seen at washed platelet
concentrations of approximately 200,000/m1 or less (Patscheke
and Worner , 1 978) .

This observation was the basis of our

first approach with PRP of platelet concentration between
400,000/pl and 450,000/ijI in aliquots to be diluted 1 : 1
with normal

saline.

selection.

These results show, possibly for the first time,

Subsequent study has confirmed the

that a direct proportionality exists between the number of
unstimulated platelets and the change in extinction that
occurs with

the event of stirring, and that this holds true

only over a well-defined range of concentrations of
platelets in PRP.

This range extends from 450,000

piatelets/p1 to concentrations as low as 100,000/pl.

Hence

the control deflection in the SCP assay, which employs the
same conditions as were used in determining the relationship
described above, can be taken as an indication of the number
of unstimulated platelets in suspension,

In an actual

assay, the picture is complicated by the presence of
variously-stimulated platelets which contribute to the
ex tinc tion .

Platelets may never assume the dimensions of

spheres (Latimer et al . , 1 977 ), but since a degree of
activation is achieved where extinction of the platelet
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suspension no longer decreases upon stirring, they must
become structures averaging to spheres.
4.3.

SignifinanttP of thf> SCP Assay

4.3.1 .

Sensitivity

The results of attempts to correlate the pattern of
platelet response in terms of the SCP assay with the
characteristics of established properties of platelet
function have provided insight into both the value of the
assay and features of the specific interaction of PAF with
sheep platelets.

The activation of platelets by PAF, as

followed by the SCP assay, is proportional to the
concentration of PAF over a range of nearly four orders of
magnitude (0.033 nM to 69 nM).

Th is cor relation is

comparable to that found with platelet aggregation but
allows quantification of lower levels of platelet activation
than practically achievable with the aggregation assay.
Since shape change can occur at concentrations of stimulus
lower than necessary for aggregation, the added sensitivity
is directly related to the initial decrease in % T that
occurs in the aggregation profile.

However, the

quantification of the latter involves measurements offering
no continuum in units and, therefore, in meaning or value,
with the other parameters of aggregation.

In contrast, the

SCP assay takes a single type of measurement, representing
shape change, over the complete range of effective
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concentrations of PAF.

Because shape change and aggregation

are separate phenomena occurring in the course of
activation, a one to one correlation between the results of
the SCP assay and those of the aggregation assay would not
be expected.
Some unreported experiments in this project have shown
that at high concentrations of PAF where the aggregation
response of the platelets is saturated, SCP is still
sensitive to increases in concentration.

The only contender

with SCP under such conditions, from among the aggregation
parameters, is the maximum slope of the aggregation profile.
Unlike the results communicated by Lapetina, in which shape
change was measured as the initial decrease in % T, the
correlation is undeniable between PAF concentration and SCP.
Furthermore, the SCP assay discriminates between
concentration changes

less

than tenfold

in magnitude, and

promises to offer even greater sensitivity to concentration
changes than so far seen.

The SCP assay should be as

effective in distinguishing concentrations of close analogs
of PAF as it is towards PAF itself. The fact that this assay
is more sensitive than aggregation to differences in the
structure of PAF analogs means that it will be more useful
in characterizing the activity of the photoaffinity1abelling analogs.
The SCP assay can also be used with washed platelets.
The extension of the range of SCP-sensitive concentrations
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of PAF in washed platelets, as compared to PRP
without precedent in aggregation studies.

is not

PAF is converted

to inactive lyso PAF by an enzyme in plasma; this is
believed to be the reason for the apparent greater activity
of PAF on platelets that have been removed from plasma by
washing (Touqui

et al ., 1 983 ).

Correlations between PAF-stimu1 ated platelet function
and SCP can also be found with the platelet release reaction.
ATP release proves to be concentration dependent and
correlates with SCP over the same range of PAF concentration
(1.1 nM to 17 nM).

However, SCP response can be observed at

degrees of activation which are too low to result in ATP
release.

The observation of ATP release in the absence of

serotonin release is perplexing since these substances
reside in the same class of secretion granules.

Serotonin

release is abolished by the absence of extracellular
calcium, but because ATP release was not measured under the
conditions of aggregation,
remains undefined.

its calcium ion dependence

The possibility that the apparent

discrepancy is due to a difference in sensitivity of the
serotonin release and ATP release assay techniques is
difficult to explore without a source of published normal
values for sheep platelets.
Miller and Gorman, studying ATP release in human
platelets in response to PAF

have arrived at values similar

to the ones obtained in this study (Miller and Gorman, 1982).
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Calculations done here have yielded values of 3.3 x 10"4
pmol ATP in response to 25 nM PAF and 2.7 x 10 ^ pmol ATP
with 50 nM PAF.

With their technique, they were not able to

detect ATP release for concentrations of PAF lower than 25
nM, but the response to this concentration of PAF was
approximately 3% of maximal release, obtained with a
saturating concentration of thrombin.

Since the

concentration dependence of ATP release demonstrated in this
project represents PAF at concentrations of 17 nM and lower
(1.1 nM) , we may be looking at very low, but reasonable,
levels of ATP release when measured on the scale of percent
maximal

release.

There is still

insufficient data to reveal

a calcium ion dependence of ATP release in our system.

On

the other hand, there is an unequivocal PAF concentration
dependence for these low levels of ATP release.

It is

remarkable that at concentrations of PAF lower than these
(i.e. 17 nM to 1.1 nM), only SCP is sensitive to platelet
activation.
4.3.2.

Effpptivpnpss nf Modulators

The effect of PAF on SCP, as on aggregation and ATP
release, was sensitive in varying degrees to concentrations
of prostacyclin .

Aggregation was most sensitive, followed

by ATP release and then SCP.

The effects of prostacyclin

were examined only as a means of demonstrating the
relationship of the SCP assay to existing measures of
platelet function, and its general applicability in studies
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of PAF.

The correlation of inhibition seen offers good

support for the relevance of the SCP to processes reflected
in aggregation and ATP release.
While the primary objective described in the previous
paragraph has been satisfied, the pattern of inhibition of
SCP and ATP release may also be a statement about the
requirement of a certain degree of shape change before ATP
release can occur.

Prostacyclin causes the accumulation of

cyclic AMP which may affect the processes of intracellular
calcium ion mobilization that occur with platelet
activation.

TMB-8, the putative intracellular calcium ion

antagonist, like prostacyclin, is thought of as a general
inhibitor of platelet activation.

Its powerful effect on

SCP matches that on aggregation, and it is tempting to
speculate that the pattern of inhibition of ATP release and
SCP would be similar to that of prostacyclin.
The question of modulation of PAF stimulated platelet
activation by indomethacin has bearing on the putative role
of PAF as the mediator of the third pathway of platelet
activation.
indomethacin.

In these studies, SCP was not sensitive to
If SCP is a measure of platelet activation

this result favors the argument that PAF mediates the third
pathway.

More important for this study was the question of

whether the pattern of inhibition of SCP by indomethacin was
the same as that exerted on aggregation.

Preliminary

studies with indomethacin failed to show an effect of
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indomethacin on the aggregation of sheep platelets,

These

further results can be reasonably interpreted as supporting
the lack of indomethacin effect, despite variations of the
aggregation response with time.

Thus, both SCP and

aggregation are unaffected by indomethacin.
4.3.3.

Fnnripmpnta 1

Information

This work has led to the accumulation of basic facts
about the interaction of PAF with sheep platelets and paves
the way for continuing research.

It is now known that PAF,

at nanomolar concentrations found effective in rabbits and
humans, is similarly active towards sheep platelets in PRP.
Its activity on sheep platelets is, likewise, independent of
ADP and the metabolites of arachidonic acid metabolites as
defined in other biological systems.

Interaction of PAF

with sheep platelets results in a calcium ion-independent
shape change followed by calcium ion-dependent aggregation
and serotonin release.

ATP release also occurs, and can be

observed under the conditions of the new assay of platelet
activation where extracellular calcium ion is absent.
Further, preliminary observations indicate that there is
phosphatidic acid formation under the conditions of the SCP
assay in response to PAF.
The SCP assay reveals a pattern of activity of synthetic
PAF analogs which parallels their platelet aggregatory
activity in sheep and other systems, and provides the first
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evidence of a specific receptor for PAF in sheep platelets.
Prostacyclin and TTVIB-S inhibit SCP-measured activity, as
well as aggregation, at concentrations falling within the
range effective in other biological systems.

Compared with

the diminishing response with time after platelet preparation
of the aggregation assay of PAF in our hands and others
these findings with the SCP assay

(Miller and Gorman, 1982)

strongly recommend the SCP assay both as a superior routine
assay of PAF-stimu1 ated platelet activity, and as a means of
testing photoaffinity
4.4.

labelling analogs

of PAF.

Photoaffinity-Lfthpl1ing Analogs

The task of preparing

the photoaffinity

labelling

analogs of PAF has presented problems which make the
availability of these molecules more distant than originally
perceived (Appendix B).

The proper identification and

characterization of the analogs will require their
availability at high levels of purity.
accomplished

by

various means

including

This may be
thin

layer

chromatography and high performance liquid chromatography
(HPLC) as demonstrated in several reports of experimentation
with PAF and PAF analogs found in the current literature
(Blank and Snyder, 1983; Valone et al., 1982; Alam et al.,
1983; Chilton et al., 1983).

Access to an HPLC system with

radioactive detection would simplify both the purification
and

the

determination

of

yields,

especially when

very small quantities of the highly expensive starting
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material, lyso PAF, are used.

In the first case,

commercially available radiolabel 1 ed PAF and lyso PAF would
serve as markers for the elution of the analog of PAF being
prepared, while in the second, quantitative estimation of the
radiolabel1ed product necessary for photoaffinity labelling
studies would be facilitated.
Details of the qualitative assessment of the products of
the preparative schemes have not yet been worked out.

The

procedures could require, for spectroscopic and other
chemical testing, quantities of material larger than
routinely handled in TLC or HPLC, and therefore call for a
larger scale of preliminary preparations. This may be
especially true for the preparation of the diazoacetyl
analog of PAF.
Although difficulties to be surmounted in this project
may be formidable, the identification and characterization
of a platelet receptor for PAF is worth the effort.

Such an

accomplishment would perhaps herald the modeling of a
specific antagonist which would be useful in studying the
roles of PAF in pathophysiology, while broadening our
understanding of the mechanisms of platelet activation.
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APPENDIX A
Abbreviations
AA

arachidonic acid

Ab

an tibody

ADP

adenosine-5’-diphosphate

Ag

an tigen

Ag-Ab

antigen-antibody complex

AGEPC

acetyl glyceryl ether phosphory1choline

ATP

adenosine 5’-triphosphate
% Max

an aggregation parameter (see section 3.3.)

Bm % Max

an aggregation parameter (see section 3.3.)

Bu t an oy 1

PAF

l-0-alkyl-2-butanoyl-sn-glycero-3phosphorylcholine

cAMP

3’,5’-cyclic adenylic acid

CP/CPK

creatine phosphate and creatine phosphok i nase

DCC

dicyclohexyIcarbodiimide

DE

discoechinocy tes

Diazoacety1
PAF

l-0-alkyl-2-diazoacetyl-sn-glycero-3phosphory1choline

D

discocy tes

EDTA

ethy1enediami netetracetic acid

EGTA

ethylene glycol-bis(b-amino-ethyl ether)
N,N-tetraacetic acid

FSM

Final Suspension Medium

IgE

immunoglobulin E

IgG

immunoglobulin G

Lyso PAF

1-0-alky1-2-hydroxyl-sn-glycero-3phosphory1choline
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Oleoyl PAF

1-oleoyl-2-acetyl-sn-glycero-3-phosphorylcholine

PA

phosphatidic acid

PAF

platelet activating factor

PDGF

platelet derived growth factor

PF4

platelet factor 4

PGE,

PGD,

PGI

prostaglandins

PGI2

pros tacyclin

PPP

platelet poor plasma

PRP

platelet rich plasma

Propanoyl

PAF

1-0-alky1-2-propanoyl-sn-glycero-3-

phosphory1choline
SCP

shape change parameter

SCP assay

technique of SCP determination

SE

spheroechinocy t es

SRS-A

slow reacting substance of anaphylaxis

TLC

thin layer chromatography

TMB-8

8-(diethylamino)octyl 3,4,5-trimethoxybenzoatehydrochloride

Tr ifluorodiazopropionyl PAF 1-0-alky1-2-(2-diazo-3,3,3-trifluoropro-

pionylchlorideJ-sn-glycero-S-phosphorylcholine
TXA2

thromboxane A2

WP

Washed Platelets

WS

Washing Solution

XT

percent light transmission calculated in
aggregometry

Appendix B
Photoaffinity-1ahe1 1 ing Analogs of PAF .

1.

Selection and Rationale.

The selection of probes for photoaffinity studies
usually involves a compromise between ease of synthesis and
the general criteria (see Section 1.6.1.1.).

A list of

precursor species for the generation of carbenes and
nitrenes that have been used in photoaffinity labelling
projects was consulted in the literature (Bayley and
Knowles, 1977).

Precursor groups for carbenes were

emphasized because of a greater reactivity and a higher
preference for C-H over O-H bonds as compared to nitrenes
(Bayley and Knowles, 1977 ).

The mechanisms by which

carbenes react include coordination to nucleophilic centers
(giving carbanions), addition to multiple bonds, insertion
into single bonds, and hydrogen abstraction which gives two
free radicals with the potential to couple.
reactive carbon center

When the

is adjacent to a carbon atom carrying

a hydrogen atom, the migration of the latter readily occurs
resulting in the formation of an unreactive olefin.

If this

problem is avoided by having instead a carbonyl group
adjacent to the reactive carbene center, the Wolf
rearrangement may occur, leading to a ketene with only
acylating potential.

Electron withdrawing substituents on

the carbon adjacent to the carbonyl group stabilize against
the Wolf rearrangement.
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Synthesis would be facilitated with a source of
radiolabel1ed PAF-like precursor for derivatization .

A

series of preparative reactions could begin with
radiolabel1ed PAF itself, for which a commercial supplier
existed by 1982.

However, the first commercial appearance

of radiolabel1ed lyso PAF in 1983 simplified matters by
pinpointing position 2 on the glycerol backbone as the most
practical site of derivatization .
In 1976

Westheimer’s group reported the synthesis of a

stable carbene precursor from which useful derivatives with
low tendencies to Wolf rearrangement (upon carbene formation
with irradiation) could be prepared (Chowhdry et al , 1 976 ).
This compound was 2 ,2 , 2-1rif1uorodiazo-propiony1 chloride,
and it was the fluorine substituents that enhanced the
stability of derivatives.

Since the propanoyl derivative of

lyso PAF (propanoyl PAF) has been variably described as 10
times more active than, or of equal activity to PAF, and
butanoyl PAF as only 7 times less active than PAF (Tence et
al. , 1981; Demopoulos et al. , 1 979 ), the
trifluorodiazopropionyl derivative of lyso PAF
(trifluorodiazopropiony1 PAF) is a firm candidate for
testing.

The known reactivity of acid chlorides and

alcohols suggests a ready preparative scheme and supports
the decision to begin with lyso PAF.
The diazoacetyl derivative of lyso PAF (diazoacetyl PAF)
is closer in structure to PAF than trifluorodiazopropiony1
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PAF

and is therefore more likely to approximate the platelet

stimulating activity of PAF.

However, the properties of the

diazoacetyl group indicate that the derivative should be less
stable than the trif1uorodiazopropiony1 analog of PAF and
produce a carbene more susceptible to the Wolf rearrangement.
Reaction schemes were planned for the preparation of both of
these photoaffinity-labelling analogs of PAF and are
outlined below.
2.

Prppflrative Sohpmps

A.

1-O-alkyl-2-(2-diazo-3,3,3-trifluoropropionylchloride)sn-glycero-3-phosphorylcholine.
Step 1.

CF3CH2NH3+C1"

+ NaN02

^

CF3CHN2

+ NaCl

Step 2.

cf3chn2

+ coci2

CF3CN2C0C1

+ HC1

+

2H20
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Step 3.
H2C-OCH2(ai2)14CH3
GHC13
CF3CN2C0C1

+

HO-C-H

>

1

+,

,

H2C-0P03CH2CH2N (CH3 )3

K

H2c-oai2(ai2)14ai3
+

CF3CN2C02-C-H

N 0 Cl
H

H2C-OP03Oi2CH2N + (ai3 )3

B.

1-O-a1kyl-2-diazoacetyl-sn-glycero-S-phosphorycholine.
Step 1 .

H2c-ooi2(ai2)14ai3
+

HO-C-H

I

DCC
CH2C02NHCH2COOH

H2C-0P03CH2CH2N (Oi3)3

H2C-OCH2(CH2)14CH3
ai2C02NHCH2C02-C-H
H 2C-0P03CH 2CH 2N + (OH 3 ) 3

+ (

)2C0
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Step 2.

H2C-OGH2(CH2)14CH3
HBr

ch2co2nhch2co2-c-h
H2C-0P03CH2CH2N + (ai3)3

H2C-OCH2(CH2)14CH3
Br-NH3+CH2C02-C-H
2^

H

-0P03CH 2CH 2N + (CH 3 ) 3

S t ep 3 .

h2c-och2(ch2)]4ch3
Br-NH3+CH2C02-C-H

hno2

H2C-0P03CH2CH2N+(CH3) 3

H2C-OCH2(C«2)]4CH3
chn2oo2-c-h
H2C-0P03CH2CH2N + (CH3 ) 3
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3.

Prppflrativp Prnnpdurp»s find Results

Tr i f1uorodiazoethane may

be prepared using

the

procedure of Gilman and Jones (Gilman and Jones, 1943).
Attempts to prepare trif1uorodiazopropiony1 chi oride from
trifluorodiazoethane and phosgene with present modifications
of the incompletely reported methods of Chowdhry and colleagues
(Chowdhry et al., 1976) have been unsuccessful.
Diazoacetyl PAF may possibly be prepared by modifications
of the procedure of Browne and colleagues (Browne et al . ,
1971) but methods have yet to be developed for the
purification of the specific products of individual steps
in this project.

